CN108366893B - Absorbent article - Google Patents

Abstract

An absorbent article (1) comprises an absorbent body (4) having a super absorbent polymer (41), pulp (42) and a blood agglutinating agent (43), and a front sheet (2) and a back sheet (3) sandwiching the absorbent body (4). The absorbent body (4) has, in cross section, a polymer-rich region (PT) in which the mass ratio of the superabsorbent polymer to the total amount of the mass of the pulp (42) and the mass of the superabsorbent polymer (41) is relatively high, and a pulp-rich region (FT) in which the mass ratio is relatively low compared to the polymer-rich region (PT). The blood agglutinant (43) is present at least in the pulp-rich region (FT) at the portion where the pulp-rich region (FT) is disposed on the skin-facing surface side for use.

Description

Absorbent article

Technical Field

The present invention relates to an absorbent article.

Background

There is known a technique of applying an agent that acts on blood itself to change the state of blood to an absorbent article to improve various performances of the absorbent article. Patent document 1 discloses a sanitary napkin including an absorbent pad containing a salt having a polyvalent ion. Patent document 2 discloses a sanitary napkin containing a partially hydrated dicarboxylic anhydride copolymer or a polycation as a blood gelling agent. Patent document 3 proposes a personal care absorbent article containing a triblock polymer containing polypropylene oxide and polyethylene oxide or a polycation as a fluid treatment material.

The present applicant has previously proposed an absorbent article in which an absorbent core contains a blood coagulating agent containing a water-soluble metal compound (see patent document 4).

Documents of the prior art

Patent document

Patent document 1: japanese examined patent publication (Kokoku) No. 38-17449

Patent document 2: japanese laid-open patent publication No. 57-153648

Patent document 3: japanese Kohyo publication 2002-528232

Patent document 4: japanese patent laid-open publication No. 2005-287997

Disclosure of Invention

The present invention is an absorbent article comprising an absorbent body containing a super absorbent polymer, hydrophilic fibers and a blood agglutinant, and a front sheet and a back sheet sandwiching the absorbent body. The absorbent body has, in cross section, a polymer-rich region in which the mass ratio of the superabsorbent polymer to the total amount of the mass of the hydrophilic fibers and the mass of the superabsorbent polymer is relatively high, and a hydrophilic fiber-rich region in which the mass ratio is relatively low compared to the polymer-rich region. The blood agglutinating agent is present at least in the hydrophilic fiber-rich region at a portion where the hydrophilic fiber-rich region is disposed on the skin-facing surface side for use.

Drawings

Fig. 1 is a plan view of a sanitary napkin which is a preferred embodiment of the menstrual blood absorbing absorbent article of the present invention.

Fig. 2 is a plan view showing a skin-facing surface side (topsheet side) of an absorbent body of the sanitary napkin shown in fig. 1.

Fig. 3 is a sectional view schematically showing a section taken along line III-III of fig. 1.

Fig. 4 is an enlarged cross-sectional view of an absorbent body included in the sanitary napkin shown in fig. 1.

Fig. 5 is an enlarged schematic sectional view of a main part of 1 sheet of the absorbent sheet constituting the absorbent body shown in fig. 4.

Fig. 6 is an enlarged cross-sectional view of an absorbent body of another embodiment of the absorbent article of the present invention.

Fig. 7 is an enlarged cross-sectional view of an absorbent body of another embodiment of the absorbent article of the present invention.

Detailed Description

Patent documents 1 and 4 do not disclose any means for improving the absorption rate of blood except for using a water-soluble metal compound as a blood coagulating agent. On the other hand, although the absorbent articles described in patent documents 2 and 3 describe that a fluid treatment agent containing a polycation can be used, only data on a nonionic treatment material is actually disclosed. In addition, in the techniques disclosed in these, it takes time to absorb blood, and side leakage of menstrual blood is likely to occur.

Accordingly, an object of the present invention is to provide an absorbent article that can solve the above-described drawbacks of the conventional art.

Hereinafter, an absorbent article of the present invention will be described based on a sanitary napkin 1 (hereinafter also referred to as "sanitary napkin 1") as a preferred embodiment thereof, with reference to the drawings. The sanitary napkin 1 comprises an absorbent body 4, and a front sheet 2 and a back sheet 3 sandwiching the absorbent body 4, wherein the absorbent body 4 comprises an absorbent sheet containing a super absorbent polymer 41, a hydrophilic fiber and a blood agglutinating agent 43. In the sanitary napkin 1 of the present embodiment, the absorbent body 4 is formed of an absorbent sheet, specifically, a structure in which a plurality of absorbent sheets are stacked in the thickness direction. In fig. 1, a plan view of a sanitary napkin which is a preferred embodiment of the absorbent article for menstrual blood absorption of the present invention is shown, and in fig. 2, a plan view of the skin-facing surface side (topsheet side) of the absorbent body shown in fig. 1 is shown. Fig. 3 shows a cross-sectional view of the sanitary napkin 1 according to the present embodiment. Further, the absorbent article of the present invention is preferably used for menstrual blood absorption use.

In the present embodiment, as shown in fig. 1 to 3, the sanitary napkin 1 has an absorbent body 10, and the absorbent body 10 includes a liquid-permeable front sheet 2 forming a skin-facing surface, a back sheet 3 forming a non-skin-facing surface, and an absorbent body 4 which is present between the two sheets 2, 3 and includes an absorbent sheet containing pulp 42 and a blood agglutinating agent 43.

As shown in fig. 1, the absorbent body 10 of the sanitary napkin 1 has a discharge portion facing portion B disposed to face a discharge portion (vaginal opening or the like) of a wearer when worn, a front portion a disposed on the abdomen side (front side) of the wearer relative to the discharge portion facing portion B, and a rear portion C disposed on the back side (rear side) of the wearer relative to the discharge portion facing portion B. The sanitary napkin 1 and the absorbent main body 10 have a longitudinal direction X corresponding to the front-rear direction of the wearer and a transverse direction Y orthogonal to the longitudinal direction X. That is, the absorbent main body 10 is divided into a front portion a, a discharge portion facing portion B, and a rear portion C in this order in the longitudinal direction X.

In the present specification, the skin-facing surface is a surface of the sanitary napkin 1 or a component thereof (for example, the topsheet 2) that faces the skin side of the wearer when worn, and the non-skin-facing surface is a surface of the sanitary napkin 1 or a component thereof that faces the opposite side (the clothing side) to the skin side when worn. The longitudinal direction X coincides with the longitudinal direction of the sanitary napkin 1 and the absorbent main body 10, and the transverse direction Y coincides with the width direction (direction orthogonal to the longitudinal direction) of the sanitary napkin 1 and the absorbent main body 10.

In the present embodiment, as shown in fig. 1 and 3, the sanitary napkin 1 includes, in addition to the absorbent main body 10, a pair of wing portions 10W, 10W extending outward in the transverse direction Y from both side portions in the longitudinal direction X of the excretion portion-corresponding portion B in the absorbent main body 10.

In the absorbent article of the present invention, the excretion portion-corresponding portion B, when having the wing-protecting portion 10W as in the sanitary napkin 1 of the present embodiment, refers to a region having the wing-protecting portion 10W in the longitudinal direction of the absorbent article (the longitudinal direction of the absorbent article, the X direction in the drawing) (a region between the base portion in the longitudinal direction X of the wing-protecting portion 10W on one side and the base portion in the longitudinal direction X of the wing-protecting portion 10W on the other side). The excretion portion facing portion B of the absorbent article having no flap portion is a region surrounded by the first folding line and the second folding line from the front end of the absorbent article in the longitudinal direction X, with respect to 2 folding lines (not shown) extending in the transverse direction (the width direction of the absorbent article, the Y direction in the drawing) generated when the absorbent article is folded into a three-folded single package form.

In the sanitary napkin 1 of the present embodiment, as shown in fig. 1, the topsheet 2 covers the entire skin-facing surface of the absorbent body 4 and extends outward in the transverse direction Y from both side edges of the absorbent body 4 in the longitudinal direction X. On the other hand, the back sheet 3 covers the entire region of the absorbent body 4 other than the skin-facing surface, and further extends outward in the lateral direction Y from both side edges of the absorbent body 4 in the longitudinal direction X, and forms side flaps 10S together with the side sheets 7 described below. The front sheet 2 and the back sheet 3 are joined to each other at extending portions from both edges in the longitudinal direction X of the absorbent body 4 by a known joining method such as an adhesive, heat sealing, ultrasonic sealing, or the like. The front sheet 2 and the back sheet 3 may be bonded to the absorbent body 4 with an adhesive.

In the sanitary napkin 1, as shown in fig. 1 and 3, the side sheets 7 are disposed on both side portions in the longitudinal direction X of the skin-facing surface of the absorbent main body 10 (the skin-facing surface of the topsheet 2). Preferably, the side sheets 7 are disposed over the entire length in the longitudinal direction X of the absorbent main body 10 so as to overlap with both the left and right side portions of the absorbent body 4 in the longitudinal direction X in plan view.

In the sanitary napkin 1, as shown in fig. 1, the pair of side sheets 7 and 7 are joined to the topsheet 2 at a linear first join line 61 located at the excretory part facing portion B and linear second join lines 62 located in the front and rear (front part a and rear part C) of the first join line 61 in the longitudinal direction X. The first join line 61 is curved so as to protrude outward in the lateral direction Y in a plan view, and the second join line 62 is linear (zigzag) so as to alternately intersect in the vertical direction in a plan view. When the first joining line 61 and the second joining line 62 are joined to the front sheet 2 and fixed to the skin-facing surface of the absorbent main body 10 in this manner, the side sheet 7 forms a space P defined by the side sheet 7 and the front sheet 2 on the inner side in the lateral direction Y than the first joining line 61 and the second joining line 62, as shown in fig. 3. Since the space P opens toward the center of the absorbent main body 10 in the lateral direction Y, body fluid such as menstrual blood flowing outward from the center of the lateral direction Y is contained in the space P, and as a result, leakage of body fluid can be effectively prevented. Further, the elastic member extending in the longitudinal direction X may be disposed at the free end portions of the pair of side pieces 7 and 7, and the pair of leakage preventing cuffs extending in the longitudinal direction X may be disposed. The leak-proof cuff has standing property and can prevent the side leakage of menstrual blood excreted on the skin-facing surface.

In the sanitary napkin 1, as shown in fig. 1, the flap portions 10S protrude greatly outward in the transverse direction Y at the excretion portion-corresponding portions B, and thus a pair of flap portions 10W, 10W extend on both the left and right sides of the absorbent main body 10 in the longitudinal direction X. As shown in fig. 1, the front sheet 2 and the back sheet 3 extend outward in the longitudinal direction X from the front end and the rear end of the absorbent body 4 in the longitudinal direction X, and are joined to each other at these extending portions by a known joining method such as an adhesive, heat seal, or ultrasonic seal to form end seals.

The wing-protecting portion 10W is a portion to be folded back to the non-skin-facing surface side of the crotch portion of the clothing such as shorts. In the sanitary napkin 1, as shown in fig. 1, the flap portions 10W have a substantially trapezoidal shape in plan view, with the lower base (side longer than the upper base) positioned on the side portion side of the absorbent main body 10 in the longitudinal direction X. A flap portion adhesive portion (not shown) for fixing the flap portion 10W (sanitary napkin 1) to a garment (not shown) such as shorts is formed on the non-skin-facing surface of the flap portion 10W, and the flap portion 10W folded back to the non-skin-facing surface (outer surface) side of the crotch portion of the garment can be adhesively fixed to the crotch portion by the flap portion adhesive portion in use. Further, a body attachment part (not shown) for attaching the absorbent body 10 to clothing such as shorts is also formed on the non-skin-facing surface of the absorbent body 10.

In the present embodiment, as shown in fig. 3, the sanitary napkin 1 has a second sheet 5 made of nonwoven fabric disposed between the topsheet 2 and the absorbent body 4. As shown in fig. 3, the second sheet 5 covers substantially the entire area of the skin-facing surface of the absorbent body 4 in the sanitary napkin 1. The second sheet 5 is a sheet that is independent of the topsheet 2 and the absorbent body 4 and is also referred to as a sub-sheet in the art. The second sheet 5 is a sheet that functions to improve the permeability of liquid from the topsheet 2 to the absorbent body 4, or to reduce the liquid returning from the liquid absorbed in the absorbent body 4 to the topsheet 2. In the sanitary napkin 1, the second sheet 5 is a sheet containing no blood agglutinating agent 43 described below.

Fig. 4 shows an enlarged cross-sectional view of the absorbent body 4 in the cross-sectional view shown in fig. 3. Fig. 5 is an enlarged sectional view of a main portion of 1 absorbent sheet constituting the absorbent body 4 shown in fig. 4. As shown in fig. 5, the absorbent body 4 including the absorbent sheet has superabsorbent polymers 41 three-dimensionally distributed, pulp 42 as hydrophilic fibers, and a blood agglutinating agent 43. The absorbent sheet 4 has a polymer-rich region PT in which the mass ratio of the superabsorbent polymer 41 to the total amount of the mass of the pulp 42 and the mass of the superabsorbent polymer 41 is relatively high, and a pulp-rich region FT as a hydrophilic fiber-rich region in which the mass ratio is relatively low compared to the polymer-rich region PT, when viewed in cross section. In the sanitary napkin 1, the polymer-rich region PT and the pulp-rich region FT are divided in the thickness direction of the absorbent sheet 4. The absorbent body 4 including the absorbent sheet contains pulp 42 and is formed into an integral structure containing therein a super absorbent polymer 41 and a blood agglutinating agent 43. As the absorbent body 4 including the absorbent sheet, it is possible to use an absorbent body or the like which is made into a sheet shape by bonding the pulps 42 to each other or between the super absorbent polymer 41 and the pulp 42 through the adhesive force of the super absorbent polymer 41 in a wet state or a separately added adhesive such as an adhesive agent or adhesive fibers. The absorbent sheet is an absorbent body formed into a sheet shape, and is distinguished from an absorbent body having a structure in which absorbent materials are generally stacked. Representative examples of the absorbent sheet include a sheet described in japanese patent No. 2963647 and a sheet described in japanese patent No. 2955223.

As the super absorbent polymer 41 included in the absorbent body 4, a granular super absorbent polymer is generally used, but a fibrous super absorbent polymer may be used. When the particulate super absorbent polymer is used, the shape thereof may be any of a spherical shape, a block shape, a bag shape, or an amorphous shape. As the super absorbent polymer, a polymer or copolymer of acrylic acid or an alkali metal salt of acrylic acid can be generally used. Examples thereof include polyacrylic acid and salts thereof and polymethacrylic acid and salts thereof. As the polyacrylate or polymethacrylate, a sodium salt can be preferably used. Further, a copolymer obtained by copolymerizing a comonomer such as maleic acid, itaconic acid, acrylamide, 2-acrylamido-2-methylpropanesulfonic acid, 2- (meth) acryloylethanesulfonic acid, 2-hydroxyethyl (meth) acrylate, or styrenesulfonic acid with acrylic acid or methacrylic acid in such a range that the performance of the super absorbent polymer is not deteriorated can also be used.

Examples of the hydrophilic fiber included in the absorbent body 4 include a hydrophilic fiber obtained by hydrophilizing a hydrophobic fiber and a fiber itself having hydrophilicity. Particularly preferred are fibers which are hydrophilic in nature and have water retention properties. The latter hydrophilic fiber is preferably natural fiber, cellulose regenerated fiber or semi-synthetic fiber. The hydrophilic fiber is particularly preferably pulp or rayon, and more preferably pulp. In the sanitary napkin 1, pulp is used as the hydrophilic fiber. For example, crosslinked cellulose fibers obtained by further crosslinking cellulose fibers intramolecularly and/or intermolecularly, or bulky cellulose fibers obtained by mercerizing wood pulp may be used. Examples of the pulp 42 include, but are not limited to, natural cellulose fibers such as wood pulp of softwood kraft pulp or hardwood kraft pulp, kapok pulp, and straw pulp. These pulps may be used in 1 or 2 or more.

The absorbent article of the present invention contains the blood agglutinating agent 43 in the absorbent body 4. Hereinafter, the blood agglutinating agent used in the present invention will be described. The blood agglutinating agent used in the present invention is an agglutinating agent that agglutinates red blood cells in blood to form an agglutinated mass of red blood cells and is capable of separating from plasma components, and is preferably an agglutinating agent having the following properties.

That is, the hemagglutination agent is an agglutination agent which agglutinates at least 2 red blood cells to form an agglutinated mass while maintaining the fluidity of blood when 1000ppm of a measurement sample agent is added to the simulated blood.

The above-mentioned simulated blood was obtained by preparing a ratio of blood cells to blood plasma of defibrinated horse blood (manufactured by NIPPONBIO-TEST) so that the viscosity thereof became 8 mPas as measured with a type-B viscometer (model TVB-10M manufactured by Toyobo industries, Ltd., measurement conditions: spindle No.19, 30rpm, 25 ℃ C., 60 seconds).

The term "state in which the fluidity of blood is maintained" means a state in which 10g of the above-mentioned simulated blood to which 1000ppm of a measurement sample agent is added is put into a spiral vial (product number "spiral tube No. 4" manufactured by Maruemu, having an inner diameter of 14.5mm, a main body diameter of 27mm, and a total length of 55mm), and when the spiral vial into which the simulated blood is put is inverted by 180 degrees, the simulated menstrual blood flows down in a volume of 60% or more within 20 seconds.

Whether "2 or more red blood cells agglutinate to form an agglutinated mass" is determined as follows. That is, the simulated blood added with 1000ppm of the measurement sample agent is diluted 4000 times with physiological saline, and it is judged that "2 or more erythrocytes are aggregated and aggregated to form an aggregate" when the median diameter of the volume average particle diameter measured at 25 ℃ is 10 μm or more corresponding to the size of an aggregate formed by aggregating 2 or more erythrocytes by a laser diffraction/scattering method using a laser diffraction/scattering particle size distribution measuring apparatus (model number: LA-950V2 manufactured by HORIBA Co., measurement conditions: flow cell measurement, circulation rate 1, no ultrasonic wave).

The sanitary napkin 1 contains a cationic polymer as the blood agglutinating agent 43 of the absorbent body 4. Examples of the cationic polymer include cationized cellulose and cationized starch such as hydroxypropyltrimethylammonium chloride starch. The blood coagulant 43 may contain a quaternary ammonium salt homopolymer, a quaternary ammonium salt copolymer, or a quaternary ammonium salt polycondensate as the cationic polymer. The "quaternary ammonium salt" in the present invention includes a compound having a positive monovalent charge at the position of a nitrogen atom or a compound generating a positive monovalent charge at the position of a nitrogen atom by neutralization, and specific examples thereof include a quaternary ammonium cation salt, a neutralized salt of a tertiary amine, and a tertiary amine having a cation in an aqueous solution. The "quaternary ammonium moiety" described below is also used in the same sense, and is a moiety positively charged in water. In the present invention, the term "copolymer" refers to a polymer obtained by copolymerization of 2 or more polymerizable monomers, and includes both binary copolymers and ternary or higher copolymers. The "polycondensate" in the present invention means a polycondensate obtained by polymerizing a condensate containing 2 or more monomers. When the blood coagulation agent 43 contains a quaternary ammonium salt homopolymer and/or a quaternary ammonium salt copolymer and/or a quaternary ammonium salt polycondensate as the cationic polymer, the blood coagulation agent 43 may contain any one of a quaternary ammonium salt homopolymer, a quaternary ammonium salt copolymer, and a quaternary ammonium salt polycondensate, or may contain a combination of any 2 or more. The quaternary ammonium salt homopolymer may be used alone in 1 kind or in combination of 2 or more kinds. Similarly, the quaternary ammonium salt copolymer can be used alone in 1 or in combination with 2 or more. Similarly, 1 kind of the quaternary ammonium salt polycondensate may be used alone or 2 or more kinds may be used in combination. In the present specification, the term "blood agglutinating agent" refers to a compound or a combination thereof capable of agglutinating red blood cells of blood, and further to an agglutinating agent capable of expressing agglutination of red blood cells by the combination of compounds. That is, the blood agglutinating agent is limited to only an agglutinating agent having a hemagglutination effect. Therefore, in the case where the third component is contained in the blood agglutinating agent, it is expressed as a blood agglutinating agent composition, and is distinguished from the blood agglutinating agent.

Among the various cationic polymers, quaternary ammonium salt homopolymers, quaternary ammonium salt copolymers, or quaternary ammonium salt polycondensates are particularly preferably used in view of adsorption to red blood cells. In the following description, for the sake of simplicity, the quaternary ammonium salt homopolymer, the quaternary ammonium salt copolymer, and the quaternary ammonium salt polycondensate are collectively referred to as "quaternary ammonium salt polymer".

The quaternary ammonium salt homopolymer is obtained by polymerizing 1 kind of polymerizable monomer having a quaternary ammonium moiety. On the other hand, the quaternary ammonium salt copolymer is obtained by copolymerizing at least 1 kind of polymerizable monomer having a quaternary ammonium moiety and, if necessary, at least 1 kind of polymerizable monomer having no quaternary ammonium moiety. That is, the quaternary ammonium salt copolymer is obtained by copolymerizing 2 or more kinds of polymerizable monomers having a quaternary ammonium moiety, or by copolymerizing 1 or more kinds of polymerizable monomers having a quaternary ammonium moiety and 1 or more kinds of polymerizable monomers having no quaternary ammonium moiety. The quaternary ammonium salt copolymer may be a random copolymer, an alternating copolymer, a block copolymer, or a graft copolymer. The quaternary ammonium salt polycondensate is obtained by using condensates containing 1 or more monomers having a quaternary ammonium site and polymerizing these condensates. That is, the quaternary ammonium salt polycondensate is obtained by polymerizing a condensate of 2 or more monomers having a quaternary ammonium moiety, or by polycondensing a condensate of 1 or more monomers having a quaternary ammonium moiety and 1 or more monomers having no quaternary ammonium moiety.

The quaternary ammonium salt polymer is a cationic polymer having a quaternary ammonium site. The quaternary ammonium moiety can be formed by quaternizing a tertiary amine with an alkylating agent. Or the tertiary amine can be generated by dissolving in acid or water and neutralizing. Or can be formed by quaternization by a nucleophilic reaction involving a condensation reaction. Examples of the alkylating agent include halogenated alkyl groups and dialkyl sulfates such as dimethyl sulfate and dimethyl sulfate. The use of dialkyl sulfate among these alkylating agents is preferable because the problem of corrosion which may occur when a halogenated alkyl group is used does not occur. Examples of the acid include hydrochloric acid, sulfuric acid, nitric acid, acetic acid, citric acid, phosphoric acid, fluorosulfonic acid, boric acid, chromic acid, lactic acid, oxalic acid, tartaric acid, gluconic acid, formic acid, ascorbic acid, and hyaluronic acid. In particular, the use of a quaternary ammonium salt polymer in which tertiary amine sites are quaternized with an alkylating agent is preferable because it can reliably neutralize the electric double layer of red blood cells. Quaternization by a nucleophilic reaction including a condensation reaction can occur, for example, in a ring-opening polycondensation reaction of dimethylamine and epichlorohydrin or a cyclization reaction of dicyandiamide and diethylenetriamine.

The inventors of the present invention have found, as a result of their studies, that the use of a cationic polymer is particularly effective for forming a coagulated mass of red blood cells in menstrual blood. The reason for this is as follows. The red blood cells have a red blood cell membrane on their surface. The erythrocyte membrane has a double-layer structure. The bilayer structure includes a lower erythrocyte membrane skeleton and an upper lipid membrane. The lipid membrane exposed on the surface of red blood cells contains a protein called glycophorin. Glycophorin has a sugar chain to which an anionically charged sugar called sialic acid is bonded at its terminal. As a result, the red blood cells can be treated as colloid particles having an anionic charge. The colloidal particles are agglomerated by using an aggregating agent. In view of the fact that red blood cells are anionic colloidal particles, it is advantageous to use a cationic substance as a coagulant in order to neutralize the electric double layer of red blood cells. Further, if the aggregating agent has a polymer chain, the polymer chains of the aggregating agent adsorbed on the surface of red blood cells are likely to be entangled with each other, thereby promoting aggregation of red blood cells. When the agglutinating agent has a functional group, agglutination of red blood cells is also promoted by the interaction between the functional groups, which is preferable.

From the viewpoint of efficiently producing a clump of red blood cells, the molecular weight of the cationic polymer is preferably 2000 or more, more preferably 1 ten thousand or more, and still more preferably 3 ten thousand or more. When the molecular weight of the cationic polymer is not less than these values, entanglement of the cationic polymer between erythrocytes or crosslinking of the cationic polymer between erythrocytes are sufficiently generated. The upper limit of the molecular weight is preferably 1000 ten thousand or less, more preferably 500 ten thousand or less, and still more preferably 300 ten thousand or less. When the molecular weight of the cationic polymer is not more than these values, the cationic polymer is favorably dissolved in menstrual blood. The molecular weight of the cationic polymer is preferably 2000 to 1000 ten thousand, more preferably 2000 to 500 ten thousand, even more preferably 2000 to 300 ten thousand, still more preferably 1 to 300 ten thousand, and particularly preferably 3 to 300 ten thousand. The molecular weight in the present invention means a weight average molecular weight. The molecular weight of the cationic polymer can be controlled by appropriately selecting the polymerization conditions. The molecular weight of the cationic polymer can be measured by using HLC-8320GPC manufactured by Tosoh corporation. Specific measurement conditions are as follows. As column, the column temperature: a guard column alpha manufactured by Tosoh corporation and an analytical column alpha-M were connected in series at 40 ℃. The detector uses RI (refractive index). As a sample to be measured, 1mg of the treatment agent (quaternary ammonium salt polymer) to be measured was dissolved in 1mL of an eluent. As the copolymer containing a water-soluble polymerizable monomer such as hydroxyethyl methacrylate, an eluent prepared by dissolving 150mmol/L sodium sulfate and 1 mass% acetic acid in water was used. As the copolymer containing a water-soluble polymerizable monomer such as hydroxyethyl methacrylate, an amylopectin mixture having a molecular weight of 5900, an amylopectin having a molecular weight of 47300, an amylopectin having a molecular weight of 21.2 ten thousand, and an amylopectin having a molecular weight of 78.8 ten thousand each dissolved in 2.5mg of an eluent 10mL was used in terms of molecular weight. The copolymer containing a water-soluble polymerizable monomer such as hydroxyethyl methacrylate is prepared at a flow rate of: 1.0mL/min, injection amount: measured under the condition of 100. mu.L. In addition to the copolymer containing a water-soluble polymerizable monomer such as hydroxyethyl methacrylate, an eluent prepared by dissolving 50mmol/L of lithium bromide and 1 mass% of acetic acid in ethanol/water/3/7 (volume ratio) was used. In addition to the copolymer containing a water-soluble polymerizable monomer such as hydroxyethyl methacrylate, a PEG-PEO mixture was used in which 10mg of each of polyethylene glycol (PEG) having a molecular weight of 106, PEG having a molecular weight of 400, PEG having a molecular weight of 1470, PEG having a molecular weight of 6450, polyethylene oxide (PEO) having a molecular weight of 5 ten thousand, PEO having a molecular weight of 23.5 ten thousand, and PEO having a molecular weight of 87.5 ten thousand was dissolved in 20mL of an eluent in terms of molecular weight. In addition to a copolymer containing a water-soluble polymerizable monomer such as hydroxyethyl methacrylate, the flow rate: 0.6mL/min, injection amount: measured under the condition of 100. mu.L.

From the viewpoint of more efficiently producing an aggregate of red blood cells, when a quaternary ammonium salt polymer is used as the cationic polymer, the quaternary ammonium salt polymer preferably has a flow potential of 1500 μ eq/L or more, more preferably 2000 μ eq/L or more, still more preferably 3000 μ eq/L or more, and still more preferably 4000 μ eq/L or more. By setting the flow potential of the quaternary ammonium salt polymer to be equal to or higher than these values, the electric double layer of red blood cells can be sufficiently neutralized. The upper limit of the flow potential is preferably 13000. mu. eq/L or less, more preferably 8000. mu. eq/L or less, and still more preferably 6000. mu. eq/L or less. By setting the flow potential of the quaternary ammonium salt polymer to be equal to or lower than these values, electrical repulsion between the quaternary ammonium salt polymers adsorbed to red blood cells can be effectively prevented. The flow potential of the quaternary ammonium salt polymer is preferably 1500. mu. eq/L or more and 13000. mu. eq/L or less, more preferably 2000. mu. eq/L or more and 13000. mu. eq/L or less, still more preferably 3000. mu. eq/L or more and 8000. mu. eq/L or less, and still more preferably 4000. mu. eq/L or more and 6000. mu. eq/L or less. The flow potential of the quaternary ammonium salt polymer can be controlled by adjusting, for example, the molecular weight of the cationic monomer itself constituting the copolymer or the copolymerization molar ratio of the cationic monomer and the anionic monomer or the nonionic monomer constituting the copolymer. The flow potential of the quaternary ammonium salt polymer can be measured using a flow potential measuring device (PCD04) manufactured by Spectris co. Specific measurement conditions are as follows. First, in a commercially available sanitary napkin, the adhesive members are thermally inactivated by a dryer or the like, and decomposed into members such as a front sheet, an absorbent body, and a back sheet. Subjecting each decomposed part to a multi-stage solvent extraction method from a nonpolar solvent to a polar solvent, and separating the treating agents for each part to obtain a solution containing a single composition. The obtained solution is dried and solidified, and the structure of the treating agent is identified by combining 1H-NMR (nuclear magnetic resonance), IR (infrared spectroscopy), LC (liquid chromatography), GC (gas chromatography), MS (mass spectrometry), GPC (gel permeation chromatography), fluorescent X-ray, and the like. A measurement sample obtained by dissolving 0.001g of a treatment agent (quaternary ammonium salt polymer) to be measured in 10g of physiological saline was titrated with a 0.001N aqueous solution of sodium polyvinyl sulfonate (0.001N aqueous solution of polydiallyldimethylammonium chloride when the measurement sample had a negative charge), and the titrated amount X mL required until the potential difference between the electrodes disappeared was measured. Then, the flow potential of the quaternary ammonium salt polymer was calculated from formula 1.

Streaming potential (X +0.190 × 1000 … formula 1

The dosage required by the normal saline of the dissolution agent is the same as the dosage of the normal saline of the dissolution agent

In order to allow the cationic polymer to be smoothly adsorbed to the surface of erythrocytes, it is advantageous that the cationic polymer easily interacts with sialic acid present on the surface of erythrocytes. From this point of view, the inventors of the present invention have conducted studies and, as a result, have found that the degree of interaction between the sialic acid conjugate and the cationic polymer can be evaluated on the basis of the ratio of the Inorganic value to the Organic value of the substance, i.e., the value of Inorganic value/Organic value (hereinafter referred to as "IOB (Inorganic Organic Balance) value"). In detail, it is shown that: as the cationic polymer, it is advantageous to use a cationic polymer having an IOB value equal to or similar to that of the sialic acid conjugate. The sialic acid conjugate is a compound in which sialic acid is present in a living body, and examples thereof include a compound in which sialic acid is bound to a terminal of a glycolipid such as a galactolipid.

In general, the behavior of a substance is largely governed by various intermolecular forces among molecules, which mainly include van der waals forces based on the molecular mass and electric affinity based on the molecular polarity. If each of van der waals force and electric affinity which greatly affect a change in a property of a substance can be separately grasped, the properties of an unknown substance or a mixture of these substances can be predicted from the combination. This research method is a theory well known as "organic conceptual graph theory". The organic concept graph theory is described in detail in, for example, "organic analysis" by rattan moore (Kaniya bookstore, 1930), and "organic qualitative analysis" by rattan moore: systematic pure substance section (co-published 1953), section "adapted chemical experimental chemistry-organic chemistry" by rattan-mule (heyday, 1971), systematic organic qualitative analysis (mixture section) by rattan-mule-akatsu-political practice (wind room study, 1974), and base and application of new organic conceptual diagram by shantian-shang-zuo-ben-shang-kufu (three co-published 2008). In the organic conceptual diagram, the degree of physical properties based mainly on van der waals forces is referred to as "organic" and the degree of physical properties based mainly on electric affinity is referred to as "inorganic" with respect to the physicochemical properties of a substance, and the physical properties of a substance are grasped by a combination of "organic" and "inorganic". While 1 carbon (C) is defined as organic 20, the inorganic and organic values of the various polar groups are defined as shown in table 1 below, the sum of the inorganic values and the organic value is obtained, and the ratio of the two is defined as the IOB value. In the present invention, the IOB value of the sialic acid conjugate is determined based on the organic value and the inorganic value, and the IOB value of the cationic polymer is determined based on the value.

[ Table 1]

Specifically, when the cationic polymer is a homopolymer, the inorganic value and the organic value are determined based on the repeating units of the homopolymer, and the IOB value is calculated. For example, in the case of poly (diallyldimethylammonium chloride) used as a cationic polymer in example 1 described later, the total of inorganic values is 400+10+10 ═ 420, and the total of organic values is 160+40 ═ 200, because the poly (diallyldimethylammonium chloride) has an organic value of-C × 8 ═ 160, an inorganic value of amine salt and NH4 salt × 1 ═ 400, an inorganic value of ring (non-aromatic monocyclic ring) × 1 ═ 10, and an organic value of-Cl × 1 ═ 40 and an inorganic value of 10. Therefore, the IOB value is 420/200 ═ 2.10.

On the other hand, when the cationic polymer is a copolymer, the IOB value is calculated in the following order from the molar ratio of the monomers used for copolymerization. That is, when the copolymer is obtained from the monomer A and the monomer B, and the organic value of the monomer A is ORA, the inorganic value is INA, the organic value of the monomer B is ORB, the inorganic value is INB, and the molar ratio of the monomer A/the monomer B is MA/MB, the IOB value of the copolymer is calculated by the following formula.

The IOB value of the cationic polymer thus determined is preferably 0.6 or more, more preferably 1.8 or more, more preferably 2.1 or more, and still more preferably 2.2 or more. The IOB value of the cationic polymer is preferably 4.6 or less, more preferably 3.6 or less, and still more preferably 3.0 or less. Specifically, the IOB value of the cationic polymer is preferably 0.6 or more and 4.6 or less, more preferably 1.8 or more and 3.6 or less, more preferably 2.1 or more and 3.6 or less, and even more preferably 2.2 or more and 3.0 or less. The IOB value of sialic acid was 4.25 in terms of sialic acid monomer and 3.89 in terms of sialic acid conjugate. The sialic acid conjugate is a substance in which a sugar chain is bonded to sialic acid in a glycolipid, and the sialic acid conjugate has a higher organic value ratio and a lower IOB value than a sialic acid monomer.

As described above, the IOB value of the cationic polymer is preferably 40 or more, more preferably 100 or more, and still more preferably 130 or more. Further, it is preferably 310 or less, more preferably 250 or less, more preferably 240 or less, and still more preferably 190 or less. For example, the organic value is preferably 40 to 310, more preferably 40 to 250, more preferably 100 to 240, and even more preferably 130 to 190. By setting the organic value of the cationic polymer in this range, the cationic polymer is more smoothly adsorbed to red blood cells.

On the other hand, the inorganic value of the cationic polymer is preferably 70 or more, more preferably 90 or more, still more preferably 100 or more, still more preferably 120 or more, and particularly preferably 250 or more. Further, it is preferably 790 or less, more preferably 750 or less, still more preferably 700 or less, still more preferably 680 or less, and particularly preferably 490 or less. For example, the inorganic value is preferably 70 to 790 inclusive, more preferably 90 to 750 inclusive, even more preferably 90 to 680 inclusive, still more preferably 120 to 680 inclusive, and particularly preferably 250 to 490 inclusive. By setting the inorganic value of the cationic polymer within this range, the cationic polymer is more favorably adsorbed to erythrocytes.

In view of allowing the cationic polymer to be more smoothly adsorbed to red blood cells, when the organic value of the cationic polymer is x and the inorganic value is y, x and y preferably satisfy the following formula a.

y＝ax(A)

In the formula, a is preferably 0.66 or more, more preferably 0.93 or more, and still more preferably 1.96 or more. Further, a is preferably 4.56 or less, more preferably 4.19 or less, and still more preferably 3.5 or less. For example, a is preferably a number of 0.66 to 4.56, more preferably a number of 0.93 to 4.19, and still more preferably a number of 1.96 to 3.5. In particular, when the organic value and the inorganic value of the cationic polymer satisfy the formula a under the condition that the organic value and the inorganic value of the cationic polymer are within the above ranges, the cationic polymer easily interacts with the sialic acid conjugate, and the cationic polymer is more easily adsorbed to erythrocytes.

The cationic polymer is preferably water-soluble from the viewpoint of efficiently producing a coagulated mass of red blood cells. In the present invention, the term "water-soluble" refers to a property that when 0.05g of a powdery cationic polymer having a particle size of 1mm or less or a film-like cationic polymer having a thickness of 0.5mm or less is added to and mixed with 50mL of ion-exchanged water at 25 ℃ in a 100mL glass beaker (5 mm. phi.), a stirring sheet having a length of 20mm and a width of 7mm is placed, and the whole amount is dissolved in water under stirring at 600rpm by using a magnetic stirrer HPS-100 manufactured by AS ONE K.K. in an amount of 24 hours or less. In the present invention, as the more preferable solubility, the total amount is preferably dissolved in water within 3 hours, and the total amount is more preferably dissolved in water within 30 minutes.

The cationic polymer is preferably a cationic polymer having a structure including a main chain and a plurality of side chains bonded to the main chain. In particular, the quaternary ammonium salt polymer is preferably a quaternary ammonium salt polymer having a structure of a main chain and a plurality of side chains bonded to the main chain. The quaternary ammonium sites are preferably present in the side chains. In this case, when the main chain and the side chain are bonded at 1 point, the flexibility of the side chain is not easily hindered, and the quaternary ammonium moiety present in the side chain is smoothly adsorbed on the surface of the red blood cell. However, in the present invention, the main chain and the side chain of the cationic polymer may be bonded at 2 or more points. In the present invention, "bonded at 1 point" means that 1 of the carbon atoms constituting the main chain is singly bonded to 1 carbon atom located at the end of the side chain. The phrase "bonded at 2 or more points" means that 2 or more of the carbon atoms constituting the main chain are each singly bonded to 2 or more carbon atoms located at the end of the side chain.

When the cationic polymer is a cationic polymer having a structure of a main chain and a plurality of side chains bonded to the main chain, for example, when the quaternary ammonium salt polymer is a quaternary ammonium salt polymer having a structure of a main chain and a plurality of side chains bonded to the main chain, the number of carbon atoms in each side chain is preferably 4 or more, more preferably 5 or more, and still more preferably 6 or more. The upper limit of the number of carbon atoms is preferably 10 or less, more preferably 9 or less, and still more preferably 8 or less. For example, the number of carbon atoms of the side chain is preferably 4 to 10, more preferably 5 to 9, and still more preferably 6 to 8. The number of carbon atoms in the side chain means the number of carbon atoms in the quaternary ammonium moiety (cationic moiety) of the side chain, and even if carbon is contained in the anion as the counter ion, the carbon is not included in the count. In particular, the number of carbon atoms in the side chain from the carbon atom bonded to the main chain to the carbon atom bonded to the quaternary nitrogen is preferably in the above range because the steric hindrance when the quaternary ammonium salt polymer is adsorbed on the surface of red blood cells is reduced.

When the quaternary ammonium salt polymer is a quaternary ammonium salt homopolymer, the homopolymer may be a polymer of a vinyl monomer having a quaternary ammonium moiety or a tertiary amine moiety, for example. In the case of polymerizing a vinyl monomer having a tertiary amine moiety, the tertiary amine moiety is quaternized with an alkylating agent before and/or after the polymerization to form a quaternary ammonium salt homopolymer, or the tertiary amine moiety is neutralized with an acid before and/or after the polymerization to form a tertiary amine neutralized salt, or a cationic tertiary amine is formed in an aqueous solution after the polymerization. Examples of alkylating agents or acids are as described above.

In particular, the quaternary ammonium salt homopolymer preferably has a repeating unit represented by the following formula 1.

In the formula, R₁Represents H or CH₃，

n represents an integer of 1 to 10 inclusive,

represents a halide ion,

Specific examples of the quaternary ammonium salt homopolymer include polyethyleneimine. Examples of the polymer having a side chain having a quaternary ammonium moiety and a main chain bonded at 1 point include poly (2-methacryloyloxyethyl dimethylamine quaternary salt), poly (2-methacryloyloxyethyl trimethyl ammonium salt), poly (2-methacryloyloxyethyl dimethylethyl ammonium methyl sulfate), poly (2-acryloyloxyethyl dimethylamine quaternary salt), poly (2-acryloyloxyethyl trimethylamine quaternary salt), poly (2-acryloyloxyethyl dimethylethyl ammonium ethyl sulfate), poly (3-dimethylaminopropyl acrylamide quaternary salt), dimethylaminoethyl methacrylate, polyallylamine hydrochloride, cationized cellulose, polyethyleneimine, polydimethylaminopropyl acrylamide, and polyamidine. On the other hand, examples of the homopolymer in which a side chain having a quaternary ammonium moiety is bonded to the main chain at 2 or more points include polydiallyldimethylammonium chloride and polydiallylamine hydrochloride.

When the quaternary ammonium salt polymer is a quaternary ammonium salt copolymer, the following copolymers can be used as the copolymer: a copolymer obtained by copolymerizing 2 or more polymerizable monomers used for the polymerization of the quaternary ammonium salt homopolymer. Alternatively, as the quaternary ammonium salt copolymer, the following copolymers can be used: a copolymer obtained by copolymerizing 1 or more polymerizable monomers used for the polymerization of the quaternary ammonium salt homopolymer with 1 or more polymerizable monomers having no quaternary ammonium moiety. In addition to or instead of the vinyl polymerizable monomer, another polymerizable monomer, for example, -SO2-, may be used. The quaternary ammonium salt copolymer may be a binary copolymer or a ternary or higher copolymer, as described above.

In particular, the quaternary ammonium salt copolymer preferably has a repeating unit represented by the above formula 1 and a repeating unit represented by the following formula 2 from the viewpoint of efficiently producing an aggregated mass of red blood cells.

In the formula, R₃Represents H or CH₃，

m represents an integer of 1 to 10 inclusive,

to represent

As the polymerizable monomer having no quaternary ammonium moiety, a cationic polymerizable monomer, an anionic polymerizable monomer, or a nonionic polymerizable monomer can be used. Among these polymerizable monomers, cationic polymerizable monomers or nonionic polymerizable monomers are particularly used, and therefore, charge balance with quaternary ammonium sites does not occur in the quaternary ammonium salt copolymer, and therefore, agglutination of red blood cells can be efficiently caused. Examples of the cationically polymerizable monomer include vinylpyridine which is a cyclic compound having a nitrogen atom with a cation under a specific condition, and a condensation compound of dicyandiamide and diethylenetriamine which is a linear compound having a nitrogen atom with a cation in the main chain under a specific condition. Examples of the anionic polymerizable monomer include 2-acrylamido-2-methylpropanesulfonic acid, methacrylic acid, acrylic acid, styrenesulfonic acid, and salts of these compounds. On the other hand, examples of the nonionic polymerizable monomer include vinyl alcohol, acrylamide, dimethylacrylamide, ethylene glycol monomethacrylate, ethylene glycol monoacrylate, hydroxyethyl methacrylate, hydroxyethyl acrylate, methyl methacrylate, methyl acrylate, ethyl methacrylate, ethyl acrylate, propyl methacrylate, propyl acrylate, butyl methacrylate, butyl acrylate, and the like. One of these cationic polymerizable monomers, anionic polymerizable monomers, or nonionic polymerizable monomers can be used, or any 2 or more thereof can be used in combination. In addition, 2 or more kinds of cationically polymerizable monomers can be used in combination, 2 or more kinds of anionically polymerizable monomers can be used in combination, or 2 or more kinds of nonionically polymerizable monomers can also be used in combination. The quaternary ammonium salt copolymer obtained by copolymerization using a cationically polymerizable monomer, an anionically polymerizable monomer and/or a nonionic polymerizable monomer as a polymerizable monomer has a molecular weight of preferably 1000 ten thousand or less, particularly preferably 500 ten thousand or less, and particularly preferably 300 ten thousand or less, as described above (the same applies to the quaternary ammonium salt copolymer exemplified below).

As the polymerizable monomer having no quaternary ammonium moiety, a polymerizable monomer having a functional group capable of forming a hydrogen bond can also be used. When such a polymerizable monomer is used for copolymerization and erythrocytes are aggregated using the quaternary ammonium salt copolymer obtained thereby, hard aggregates are likely to be generated, and the absorption performance of the super absorbent polymer is less likely to be impaired. Examples of the functional group capable of forming a hydrogen bond include-OH, -NH2, -CHO, -COOH, -HF, -SH, and the like. Examples of the polymerizable monomer having a functional group capable of forming a hydrogen bond include hydroxyethyl methacrylate, vinyl alcohol, acrylamide, dimethylacrylamide, ethylene glycol, propylene glycol, ethylene glycol monomethacrylate, ethylene glycol monoacrylate, hydroxyethyl acrylate, and the like. In particular, hydroxyethyl methacrylate, 2-hydroxyethyl methacrylate, hydroxyethyl acrylate, dimethylacrylamide and the like, which strongly act as hydrogen bonds, are preferable because the adsorption state of the quaternary ammonium salt polymer to erythrocytes is stabilized. These polymerizable monomers may be used alone in 1 kind, or in combination in 2 or more kinds.

As the polymerizable monomer having no quaternary ammonium moiety, a polymerizable monomer having a functional group capable of hydrophobic interaction can also be used. By using such a polymerizable monomer for copolymerization, the same advantageous effect as in the case of using a polymerizable monomer having a functional group capable of forming a hydrogen bond as described above, that is, the effect of easily generating hard aggregates of red blood cells is exhibited. Examples of the functional group capable of hydrophobic interaction include an alkyl group such as a methyl group, an ethyl group, or a butyl group, a phenyl group, an alkylnaphthyl group, or a fluorinated alkyl group. Examples of the polymerizable monomer having a functional group capable of hydrophobic interaction include methyl methacrylate, methyl acrylate, ethyl methacrylate, ethyl acrylate, propyl methacrylate, propyl acrylate, butyl methacrylate, butyl acrylate, styrene, and the like. In particular, methyl methacrylate, methyl acrylate, butyl methacrylate, butyl acrylate, and the like, which exhibit a strong hydrophobic interaction and do not significantly reduce the solubility of the quaternary ammonium salt polymer, are preferable because the adsorption state of the quaternary ammonium salt polymer to red blood cells is stabilized. These polymerizable monomers may be used alone in 1 kind, or in combination in 2 or more kinds.

The molar ratio of the polymerizable monomer having a quaternary ammonium moiety to the polymerizable monomer having no quaternary ammonium moiety in the quaternary ammonium salt copolymer is preferably adjusted so that erythrocytes are sufficiently aggregated by the quaternary ammonium salt copolymer. Alternatively, it is preferable to adjust the flow potential of the quaternary ammonium salt copolymer to the above value. Alternatively, the IOB of the quaternary ammonium salt copolymer is preferably adjusted to the above value. In particular, the molar ratio of the polymerizable monomer having a quaternary ammonium moiety in the quaternary ammonium salt copolymer is preferably 10 mol% or more, more preferably 22 mol% or more, still more preferably 32 mol% or more, and still more preferably 38 mol% or more. Further, it is preferably 100 mol% or less, more preferably 80 mol% or less, still more preferably 65 mol% or less, and still more preferably 56 mol% or less. Specifically, the molar ratio of the polymerizable monomer having a quaternary ammonium moiety is preferably 10 mol% or more and 100 mol% or less, more preferably 22 mol% or more and 80 mol% or less, more preferably 32 mol% or more and 65 mol% or less, and still more preferably 38 mol% or more and 56 mol% or less.

In the case where the quaternary ammonium salt polymer is a quaternary ammonium salt polycondensate, the polycondensate may be one of: a polycondensate obtained by using condensates containing 1 or more of the above monomers having a quaternary ammonium moiety and polymerizing these condensates. Specific examples thereof include dicyandiamide/diethylenetriamine polycondensates and dimethylamine/epichlorohydrin polycondensates.

The quaternary ammonium salt homopolymer and the quaternary ammonium salt copolymer can be obtained by a homopolymerization method or a copolymerization method of a vinyl polymerizable monomer. As the polymerization method, for example, radical polymerization, living cationic polymerization, living anionic polymerization, coordination polymerization, ring-opening polymerization, polycondensation, or the like can be used. The polymerization conditions are not particularly limited as long as the conditions that can obtain a quaternary ammonium salt polymer having a targeted molecular weight, flow potential, and/or IOB value are appropriately selected.

The above-described cationic polymer is an example of the above-described "preferable blood agglutinating agent 43", and the effects thereof can be referred to examples 1 to 45 of Japanese patent application No. 2015-239286.

As described above, the blood agglutinating agent 43 included in the absorbent body 4 may be provided in the form of a composition (blood agglutinating agent composition) containing a third component, for example, a solvent, a plasticizer, a fragrance, an antibacterial deodorant, a skin care agent, and the like, in addition to the polycation (cationic polymer). The blood agglutinant 43 may contain 1 or 2 or more kinds of components other than the cationic polymer. As the solvent, water, a water-soluble organic solvent such as a saturated aliphatic monohydric alcohol having 1 to 4 carbon atoms, or a mixed solvent of the water-soluble organic solvent and water can be used. As the plasticizer, glycerin, polyethylene glycol, propylene glycol, ethylene glycol, 1, 3-butylene glycol, and the like can be used. As the flavor, for example, a flavor having a green plant-based flavor, a plant extract, a citrus extract, etc. described in japanese patent No. 4776407 can be used. As the antibacterial deodorant, a metal-containing cancrinite-type mineral having antibacterial properties as described in japanese patent No. 4526271, a porous polymer obtained by polymerizing a polymerizable monomer having a phenyl group as described in japanese patent No. 4587928, a quaternary ammonium salt as described in japanese patent No. 4651392, activated carbon, a clay mineral, and the like can be used. As the skin care agent, plant extracts, collagen, natural moisturizing components, moisturizers, keratolytic agents, anti-inflammatory agents, and the like described in japanese patent No. 4084278 can be used.

The ratio of the cationic polymer in the blood coagulant composition is preferably 1% by mass or more, more preferably 3% by mass or more, and still more preferably 5% by mass or more. Further, it is preferably 50% by mass or less, more preferably 30% by mass or less, and still more preferably 10% by mass or less. For example, the ratio of the cationic polymer is preferably 1 mass% or more and 50 mass% or less, more preferably 3 mass% or more and 30 mass% or less, and still more preferably 5 mass% or more and 10 mass% or less. By setting the ratio of the cationic polymer to the blood agglutinating agent composition within this range, an effective amount of the cationic polymer can be provided to the absorbent article.

The amount of the blood agglutinant 43 contained in the absorbent sheet constituting the absorbent body 4 is preferably 0.1g/m²Above, more preferably 0.5g/m²Above, more preferably 1.5g/m²The above. Further, it is preferably 25g/m²Below, more preferably 15 g-m²Hereinafter, more preferably 10g/m²The following. For example, the amount of the blood agglutinating agent 43 is preferably 0.1g/m²Above 25g/m²Hereinafter, more preferably 0.5g/m²Above 15g/m²Hereinafter, more preferably 1.5g/m²Above 10g/m²The following. By applying the blood agglutinating agent 43 in an amount within this range, erythrocytes in excreted menstrual blood can be efficiently agglutinated. In the case where the blood agglutinating agent 43 is applied to 2 or more sites, for example, in the case where the blood agglutinating agent 43 is applied to both of the main absorbent sheet 401 and the central absorbent sheet 402, which will be described later, the amount is the sum of the blood agglutinating agents 43 applied to each site. In particular, it is preferable that the blood aggregating agent 43 is a cationic polymer and the amount of the cationic polymer contained in the absorbent sheet is in the above range.

In the sanitary napkin 1, as shown in fig. 3 and 4, the absorbent body 4 has a multilayer structure formed of absorbent sheets. Here, the multilayer structure formed as described above may be a structure in which a plurality of absorbent sheets are stacked, a structure in which 1 absorbent sheet is folded, or a structure in which these are combined. In the sanitary napkin 1, as shown in fig. 3 and 4, the absorbent body 4 includes a central absorbent sheet 402 in which the excretory part facing portion B disposed so as to face the excretory part of the wearer when worn is formed of an absorbent sheet, and a main absorbent sheet 401 covering the central absorbent sheet 402. That is, the absorbent body 4 of the sanitary napkin 1 has a multilayer structure of the main absorbent sheet 401 and the central absorbent sheet 402, and the middle-height portion 403 is formed in the excretion portion-corresponding portion B. The multi-layer structure of the absorbent body 4 of the sanitary napkin 1 has a structure in which a central absorbent sheet 402 is contained inside the folded structure of the 1-piece main body absorbent sheet 401, and the central absorbent sheet 402 is disposed in the middle height portion 403.

In the sanitary napkin 1, as shown in fig. 3 and 4, the main absorbent sheet 401 is preferably formed of a sheet having a length (width) in the transverse direction Y longer than that of the sanitary napkin 1 by 1 sheet, both side portions of the main absorbent sheet 401 in the longitudinal direction X are folded back to the back sheet 3 side to form a double-layered structure, and both side edges in the longitudinal direction X are overlapped with each other at the center in the transverse direction Y to form the outer shape of the absorbent body 4. In this way, the main absorbent sheet 401 having a double-layered structure includes a front side absorbent sheet 401a on the front sheet 2 side and a back side absorbent sheet 401b on the back sheet 3 side. The central absorbent sheet 402 is formed of 1 sheet having a rectangular shape in plan view, and has a three-layer structure in which the central absorbent sheet 402 is triple-folded in the transverse direction Y. When the central absorbent sheet 402 is formed into a three-layer structure, the second bending line from the free end in the transverse direction Y among the 2 bending lines crossing the central absorbent sheet 402 in the longitudinal direction X is bent to the back sheet 3 side, and the first bending line from the free end in the transverse direction Y is bent to the front sheet 2 side, and the free end in the transverse direction Y is spirally folded so as to be disposed inside the three-layer structure. The central absorbent sheet 402 having the three-layer structure formed by spirally forming three folds in this manner has an upper absorbent sheet 402a on the front side absorbent sheet 401a side, a lower absorbent sheet 402b on the back side absorbent sheet 401b side, and an intermediate absorbent sheet 402c between these sheets 402a and 402 b. The middle height portion 403 is formed by sandwiching a sheet having a three-layer structure including an upper absorbent sheet 402a, a middle absorbent sheet 402c, and a lower absorbent sheet 402b between a front side absorbent sheet 401a and a back side absorbent sheet 401 b. The intermediate height portion 403 is formed only in the drain portion facing portion B, and is not formed in the front portion a and the rear portion C. As shown in fig. 4, the number of the laminated absorbent sheets constituting the absorbent body 4 around the middle height portion 403 is 2, whereas the number of the laminated absorbent sheets constituting the absorbent body 4 of the middle height portion 403 is 5, and the number of the laminated absorbent sheets is large, and the thickness is large. Therefore, the raised portion 403 forms a raised portion protruding toward the topsheet 2 (the skin-facing surface side of the sanitary napkin 1) at the excretion portion-facing portion B.

The thickness of each absorbent sheet is preferably 0.1mm or more, particularly preferably 0.3mm or more, and preferably 2mm or less, particularly preferably 1.5mm or less. More specifically, from the viewpoint of obtaining an absorbent article which sufficiently includes liquid diffusibility and liquid retentivity and has good wearing feeling, it is preferably 0.1mm to 2mm, and particularly preferably 0.3mm to 1.5 mm.

The thickness of the middle-high portion 403 of the absorbent body 4 is preferably 0.7mm or more, more preferably 1mm or more, and further preferably 5mm or less, more preferably 4mm or less, more specifically preferably 0.7mm or more and 5mm or less, and more preferably 1mm or more and 4mm or less. By setting the thickness of the middle-high portion 403 in such a range, it is easy to achieve both good wearing feeling and high absorption performance in the excretion portion-corresponding portion B in which the middle-high portion 403 is formed. In addition, in the case where the absorbent article includes the wing protector portion as in the sanitary napkin 1 of the present embodiment, wrinkles of the absorbent body at the excretion portion-corresponding portion are easily suppressed when worn. The thickness of the portion other than the middle-high portion 403 of the absorbent body is preferably 0.3mm or more, more preferably 0.5mm or more, and is preferably 3mm or less, more preferably 2.5mm or less, more specifically preferably 0.3mm or more and 3mm or less, and more preferably 0.5mm or more and 2.5mm or less. This range is preferable from the viewpoint of high absorption performance and improved followability to the wearer's motion. The thicknesses of the absorbent body and the absorbent sheet were measured by the following methods.

< method for measuring thickness of absorbent sheet and absorbent body >

The absorbent sheet or the absorbent body as the object to be measured was left standing at a horizontal position without wrinkles or bends, and 5cN/cm was measured²Thickness under load. In the thickness measurement of the present invention, a thickness meter, PEACOCK DIALUPRIGHT GAUGES R5-C (manufactured by OZAKI MFG. CO. LTD.) was used. At this time, a plate (Acrylic plate having a thickness of about 5mm) which is circular or square in plan view (plate of approximately 5mm) is disposed between the distal end of the thickness gauge and the measurement portion of the object to be measured, and the size of the plate is adjusted so that the load becomes 5cN/cm²。

In the sanitary napkin 1, the blood agglutinating agent 43 is present in at least the pulp-rich region FT at the portion where the pulp-rich region FT is disposed on the skin-facing surface side for use. Here, when the absorbent body 4 has a multilayer structure formed of absorbent sheets as in the sanitary napkin 1, the blood agglutinating agent 43 may not be disposed on all the absorbent sheets forming the multilayer structure. In the sanitary napkin 1, as shown in fig. 4, the blood agglutinating agent 43 is disposed on a main absorbent sheet 401 having a two-layer structure including a front side absorbent sheet 401a and a back side absorbent sheet 401 b. As described above, since the main absorbent sheet 401 has a double-layer structure in which both side portions in the longitudinal direction X are folded back, the front side absorbent sheet 401a is used with the pulp-rich region FT disposed on the skin-facing surface side, and the back side absorbent sheet 401b is used with the pulp-rich region FT disposed on the non-skin-facing surface side. Therefore, in the middle-high portion 403, the pulp-rich region FT and the polymer-rich region PT are arranged in this order in each of the front absorbent sheet 401a, the upper absorbent sheet 402a, and the intermediate absorbent sheet 402c as viewed from the skin contact surface side, and the polymer-rich region PT and the pulp-rich region FT are arranged in this order in each of the lower absorbent sheet 402b and the back absorbent sheet 401b as viewed from the skin contact surface side. In the front absorbent sheet 401a used with the pulp-rich region FT disposed on the skin-facing surface side, the blood agglutinating agent 43 is present in the polymer-rich region PT and the pulp-rich region FT, and the amount of the blood agglutinating agent present in the pulp-rich region FT is greater than that in the polymer-rich region PT. Here, the phrase "the amount of the blood agglutinating agent 43 present is large" means that when the mass of the blood agglutinating agent 43 per unit area present in each of the regions FT and PT, that is, the grammage of the blood agglutinating agent 43 in each of the regions FT and PT is compared, the grammage of the blood agglutinating agent 43 in one region is relatively large. In the back side absorbent sheet 401b in which the pulp-rich region FT is used on the non-skin-facing surface side, in other words, the polymer-rich region PT is used on the skin-facing surface side, the blood agglutinating agent 43 is present in the polymer-rich region PT and the pulp-rich region FT, and the amount of the blood agglutinating agent present in the pulp-rich region FT is greater than that of the polymer-rich region PT. In addition, the blood agglutinating agent 43 is not disposed on the central absorbent sheet 402 forming the three-layer structure including the upper absorbent sheet 402a, the middle absorbent sheet 402c, and the lower absorbent sheet 402 b.

Whether or not the blood agglutinating agent 43 is disposed is determined as follows.

The superabsorbent polymer 41 included in the absorbent body 4, the pulp 42 included in the absorbent body 4, and the blood agglutinant 43 included in the absorbent body 4 were each subjected to elemental analysis in advance using an energy dispersive X-ray analysis apparatus (EDX) attached to a Scanning Electron Microscope (SEM). Next, a sample piece to be judged whether or not the blood agglutinating agent 43 is arranged was attached to an aluminum sample table using a carbon double-sided tape, platinum/vanadium coating was performed as necessary, and then the presence or absence of the element of the blood agglutinating agent 43 was confirmed using EDX (elemental analysis apparatus) while being enlarged by SEM observation. The measurement was carried out at an accelerating voltage of 15kV to 40 kV.

Whether or not the amount of the blood coagulant 43 present in the pulp-rich region FT is greater than the polymer-rich region PT is determined semi-quantitatively as described below.

A sample sheet composed of an absorbent sheet containing a polymer-rich region PT and a pulp-rich region FT and containing a blood agglutinant 43 was attached to an aluminum sample table using a carbon double-sided tape, platinum/vanadium coating was performed as necessary, and then elemental mapping of the super absorbent polymer 41, elemental mapping of the pulp 42, and elemental mapping of the blood agglutinant 43 were performed using EDX (elemental analysis device) while enlarging by SEM observation. The measurement was carried out at an accelerating voltage of 15kV to 40 kV. Next, the obtained maps of the element distributions are compared, and in the case where the element map of the blood agglutinating agent 43 is more similar to that of the pulp 42 than to that of the high absorbent polymer 41, it is determined that the amount of the blood agglutinating agent 43 present is larger in the pulp-rich region FT than in the polymer-rich region PT.

In addition, an absorbent sheet having a larger amount of the blood agglutinating agent 43 present in the pulp-rich region FT than in the polymer-rich region PT can be produced by selectively containing the blood agglutinating agent 43 in the pulp-rich region FT in the production step of the absorbent sheet. For example, in the case where the absorbent sheet is configured such that a pulp-rich layer as the pulp-rich region FT and a polymer-rich layer as the polymer-rich region PT are superposed on each other, the layers may be formed separately and the pulp-rich layer may contain the blood agglutinating agent 43 before being superposed on the polymer-rich layer.

For example, the case of the absorbent sheet described in japanese patent No. 2963647 will be described. A super absorbent polymer is spread on a wet web obtained by wet papermaking of an aqueous slurry containing at least hydrophilic fibers and hot-melt adhesive fibers or a paper strength agent to form a super absorbent polymer-rich layer (corresponding to a polymer-rich region PT) in which the super absorbent polymer enters between the fibers, and a fiber aggregate containing the hydrophilic fibers and the hot-melt adhesive fibers or the paper strength agent is superposed on the super absorbent polymer-rich layer and integrated, and dried to produce an absorbent sheet, whereby the superposed fiber aggregate becomes a pulp-rich layer (corresponding to a pulp-rich region FT). The amount of the coagulant present in the pulp-rich layer can be made larger than the amount of the super absorbent polymer-rich layer by previously containing the coagulant in the stacked fiber aggregate or by manufacturing the absorbent sheet while spraying or applying the coagulant to the stacked fiber aggregate in the absorbent sheet manufacturing step.

The superabsorbent polymer-dispersed layer is not limited to a wet web, and may be paper or nonwoven fabric obtained by stacking fibers into pulp or by papermaking and drying. From the viewpoint that the super absorbent polymer is likely to enter between the fibers, for example, bulky paper subjected to creping treatment, or a hot air nonwoven fabric is preferable, and as means for bonding the super absorbent polymer and the fibers of the super absorbent polymer-rich layer and the fibers of the pulp-rich layer, hot melt or water-soluble adhesive may be used. The pulp-rich layer may be formed by further fiber-stacking or blowing the hydrophilic fibers on the super absorbent polymer-rich layer. In addition, as a method of applying the coagulant, the coagulant may be sprayed or applied to the pulp-rich layer side after the absorbent sheet is manufactured.

In the sanitary napkin 1, as shown in fig. 1 to 4, a longitudinal slit 44 extending in the longitudinal direction X is provided in the excretion portion-facing portion B in the absorbent body 4. With the longitudinal slits 44, menstrual blood that has reached the absorbent body 4 easily diffuses in the longitudinal direction X and also easily permeates in the thickness direction of the absorbent body 4. In the sanitary napkin 1, the longitudinal slits 44 extending in the longitudinal direction X have slit regions 44S formed in a state of being dispersed in both the longitudinal direction X and the transverse direction Y. As shown in fig. 2, the slit region 44S in which the plurality of slits 44 are arranged extends not only over the drain portion facing portion B but also over a part of the front portion a and a part of the rear portion C. That is, the vertical slit 44 is present at least in the drain portion facing portion B, and a region including the slit 44 located in the drain portion facing portion B is referred to as a slit region 44S.

In the sanitary napkin 1, the longitudinal slits 44 preferably penetrate the absorbent sheet on the side closest to the skin-facing surface containing the blood agglutinating agent 43. In the sanitary napkin 1, the absorbent sheet on the side closest to the skin-facing surface containing the blood agglutinating agent 43 is the front side absorbent sheet 401 a. As shown in fig. 3 and 4, when the absorbent body 4 is cut in the transverse direction Y, the slits 44 need only penetrate the front side absorbent sheet 401a, but the absorbent body 4 is entirely penetrated in the thickness direction. In the sanitary napkin 1, the longitudinal slits 44 preferably penetrate through all of the 5-sheet laminate constituting the middle height portion 403, i.e., the front absorbent sheet 401a, the upper absorbent sheet 402a, the middle absorbent sheet 402c, the lower absorbent sheet 402B, and the back absorbent sheet 401B, in the excretory portion-facing portion B. In the sanitary napkin 1, the slits 44 extend through the front side absorbent sheet 401a and the back side absorbent sheet 401b in a part of the front portion a and a part of the back portion C.

In the sanitary napkin 1, the arrangement of the longitudinal slits 44 in the slit region 44S is not particularly limited as long as the longitudinal slits 44 are distributed in both the longitudinal direction X and the transverse direction Y, but preferably 4 or more slits are distributed in the central slit region 44S 1. The central slit region 44S1 is a region overlapping the central absorbent sheet 402 in the slit region 44S.

In the central slit region 44S1, the slit rows are preferably formed in 3 or more rows in the longitudinal direction X, more preferably 4 or more rows, and still more preferably 5 or more rows. The number of vertical slits 44 spaced apart in the lateral direction Y included in each slit row is preferably 2 or more, and more preferably 3 or more.

In addition to the slot rows included in the central slot region 44S1, it is preferable that the slot regions 44S1 have 1 row or 2 or more rows of slot rows in the longitudinal direction X of the slot region 44S.

The width W44 (see fig. 2) of each slit 44 in a plan view is preferably 0.1mm or more, more preferably 0.2mm or more, and preferably 1mm or less, more preferably 0.8mm or less, and preferably 0.1mm or more and 1mm or less, more preferably 0.2mm or more and 0.8mm or less.

The length (length in the longitudinal direction) L44 of the slit region 44S in a plan view of the longitudinal slit 44 is preferably 10mm or more, more preferably 15mm or more, and preferably 35mm or less, more preferably 25mm or less, and preferably 10mm or more and 35mm or less, more preferably 15mm or more and 25mm or less.

The interval (width-direction interval) D44 between the vertical slits 44 in the same slit row in the slit region 44S is preferably 3mm or more, more preferably 7mm or more, and preferably 20mm or less, more preferably 15mm or less, and preferably 3mm or more and 20mm or less, more preferably 7mm or more and 15mm or less.

The materials for forming the components of the sanitary napkin 1 of the present embodiment will be described.

As the front sheet 2 and the back sheet 3, various sheets conventionally used in absorbent articles such as sanitary napkins can be used without particular limitation. For example, a single-layer or multi-layer nonwoven fabric, an apertured film, or the like can be used as the front sheet 2. As the back sheet 3, a moisture-permeable resin film or the like can be used.

The second sheet 5 preferably contains a hydrophilic nonwoven fabric or a hydrophilic fiber aggregate. Examples of the nonwoven fabric include a through-air nonwoven fabric, a point-bond nonwoven fabric, a resin-bond nonwoven fabric, a spunlace nonwoven fabric, and an air-laid nonwoven fabric. As for the second sheet 5, the grammage thereof is preferably 10g/m²Above 50g/m²Hereinafter, more preferably 15g/m²Above 40g/m²The following. The thickness of the second sheet 5 is preferably 0.1mm to 5 mm.

In the sanitary napkin 1, it is preferable to apply an adhesive between the front sheet 2 and the second sheet 5, between the second sheet 5 and the absorbent body 4, and between the absorbent body 4 and the back sheet 3 to fix them. The adhesive can be applied using a known apparatus, for example, a slot coating gun, a spiral spray gun, a spray gun, or a spot gun, and is preferably applied spirally in the sanitary napkin 1 using a spiral spray gun. As the adhesive to be applied, for example, a hot melt adhesive is preferably used. The coating amount of the hot-melt adhesive is preferably 1.5g/m²Above 10g/m²The following.

In order to form the longitudinal slits 44 in the absorbent body 4 as in the sanitary napkin 1, the stacked body of absorbent sheets may be partially cut by a known cutting device, and for example, a cutting device having: a cutter roller having a plurality of cutting blades extending in the circumferential direction and formed on the circumferential surface of the roller in a dispersed manner in the circumferential direction and the axial length direction of the roller; and an anvil roll receiving the blade of the cutter roll.

The operation and effect and the mechanism of estimation of the sanitary napkin 1 will be explained.

In the sanitary napkin 1, as shown in fig. 5, the absorbent body 4 composed of the absorbent sheet has a polymer-rich region PT in which the superabsorbent polymer 41 is relatively large and a pulp-rich region FT in which the superabsorbent polymer 41 is relatively small in cross section, and the blood agglutinating agent 43 is present at least in the pulp-rich region FT at a portion where the pulp-rich region FT is used by being disposed on the skin-facing surface side. Therefore, in the use of the sanitary napkin 1, menstrual blood can be separated into red blood cells and plasma by the blood agglutinating agent 43 in the pulp-rich region FT on the skin-facing surface side, and then absorbed into the superabsorbent polymer 41, whereby menstrual blood can be efficiently absorbed. Further, since menstrual blood is separated into menstrual blood erythrocytes and plasma before being absorbed by the super absorbent polymer 41, plasma having a lower viscosity than blood diffuses in the pulp 42, and aggregated erythrocytes do not diffuse as much as plasma but diffuse together, thereby preventing local concentration of blood cell aggregates, increasing the absorption rate of repeatedly absorbed blood, and preventing menstrual blood from leaking laterally. In particular, in the sanitary napkin 1, the blood agglutinating agent 43 is present in the polymer-rich region PT and the pulp-rich region FT, and is present in an amount greater in the pulp-rich region FT than in the polymer-rich region PT. Therefore, a large number of blood cell aggregates can be easily dispersed and stay in the pulp-rich region FT on the skin-facing surface side, and the plasma of blood can be efficiently absorbed in the polymer-rich region PT, so that the absorption rate of blood can be easily increased, and the side leakage of menstrual blood can be further prevented.

In addition, in the sanitary napkin 1, as shown in fig. 3 and 4, the absorbent body 4 is formed in a multilayer structure formed of absorbent sheets. Therefore, a space is formed between the sheets, and this space serves as resistance, so that the blood cell aggregates formed in the front absorbent sheet 401a are less likely to migrate from the sheet 401a to the lower sheet, and the closer to the back sheet 3, the more likely the blood plasma increases, and the more likely the blood plasma diffuses. In addition, the plasma can be more easily diffused between a small space between sheets than when the plasma permeates and diffuses into the next sheet, and the absorption rate of the absorbed blood becomes higher, whereby the side leakage of menstrual blood can be further prevented.

In the sanitary napkin 1, as shown in fig. 1 to 3, the absorbent body 4 has a longitudinal slit 44 in the excretion portion-corresponding portion B. Therefore, menstrual blood can be easily moved in the longitudinal direction X, and side leakage of menstrual blood can be further prevented. In addition, a space is formed in the portion of the absorbent body 4 where the slits 44 are provided, and menstrual blood from the topsheet 2 is easily taken in, and menstrual blood easily penetrates in the thickness direction of the absorbent body 4, and menstrual blood easily penetrates in the face direction of the absorbent body 4 in the cross section of the slits 44. Therefore, even when the blood cell aggregates are present at one place on the skin contact surface side of the absorbent body 4, menstrual blood permeates into the back sheet side of the absorbent body 4 and is easily absorbed, and therefore leakage is not easily generated. In addition, when the blood aggregating agent is present on the non-skin-facing surface side of the absorbent body 4, menstrual blood can be efficiently absorbed in this region, and therefore, there is an advantage that the absorption rate is significantly increased.

In addition, since the cut portion of the vertical slit 44 is slightly compressed in the slitting process in many cases, the density is higher than that of a portion where the vertical slit 44 is not provided, and the absorption rate is further improved. Further, by making the slits 44 completely penetrate the absorbent body 4, the liquid that has reached the absorbent body 4 can easily reach the non-skin-facing surface side of the absorbent body 4, and absorption using the absorbent body 4 can be performed efficiently, which is advantageous in terms of increasing the amount of absorption and storage and suppressing the occurrence of liquid return. These effects produced by the slits provided in the absorbent body 4 are expected to be exhibited in the case where the blood coagulating agent 43 is present only in the pulp-rich region FT, in the case where the blood coagulating agent 43 is present in the polymer-rich region PT and the pulp-rich region FT and the same amount of the blood coagulating agent 43 is present in both regions, or in the case where the amount of the blood coagulating agent 43 present is greater in the pulp-rich region FT than in the polymer-rich region PT.

In the sanitary napkin 1, as shown in fig. 1 and 3, a second sheet 5 made of nonwoven fabric is disposed between the topsheet 2 and the absorbent body 4. Therefore, the blood cell aggregate formed in the absorbent body 4 is covered with the second sheet 5, and the feeling of stickiness due to the return to the surface is prevented, and the front sheet 2 side is not easily visually recognized, thereby preventing the user from feeling uncomfortable.

The present invention has been described above based on preferred embodiments thereof, but the absorbent article of the present invention is not limited to the sanitary napkin 1 of the above-described embodiments and can be modified as appropriate.

For example, in the sanitary napkin 1, the absorbent body 4 is configured by an absorbent sheet, but instead, may be configured by a type in which hydrophilic fibers and/or superabsorbent polymers are stacked, and may have a polymer-rich region and a hydrophilic fiber-rich region having different blending ratios of the hydrophilic fibers and the superabsorbent polymers on the skin-facing surface side and the non-skin-facing surface side. Further, the entire absorbent body structure of the type in which the fibers are stacked may be covered with a hydrophilic core material. However, in the case of an absorbent body having a structure in which a fiber-stacking absorbent body structure is covered with a hydrophilic core material, it is necessary to contain a blood agglutinating agent in a region rich in hydrophilic fibers other than the core.

In the sanitary napkin 1, as shown in fig. 4, the blood agglutinating agent 43 is disposed on the main absorbent sheet 401 having a two-layer structure including the front side absorbent sheet 401a and the back side absorbent sheet 401b, but as shown in fig. 6, the blood agglutinating agent 43 may be disposed on the central absorbent sheet 402 having a three-layer structure including the upper absorbent sheet 402a, the middle absorbent sheet 402c, and the lower absorbent sheet 402b, instead of the blood agglutinating agent 43 being disposed on the main absorbent sheet 401. In the absorbent body 4 shown in fig. 6, the central absorbent sheet 402 is formed into a three-layer structure of three-fold in a roll shape as described above, and therefore the upper absorbent sheet 402a and the intermediate absorbent sheet 402c are used with the pulp-rich region FT disposed on the skin-facing surface side, and the lower absorbent sheet 402b is used with the pulp-rich region FT disposed on the non-skin-facing surface side. In the upper absorbent sheet 402a and the intermediate absorbent sheet 402c used with the pulp-rich region FT disposed on the skin-facing surface side, the blood agglutinating agent 43 is present in the polymer-rich region PT and the pulp-rich region FT, and the amount of the blood agglutinating agent present in the pulp-rich region FT is greater than that in the polymer-rich region PT. In the lower absorbent sheet 402b in which the pulp-rich region FT is used on the non-skin-facing surface side, in other words, the polymer-rich region PT is used on the skin-facing surface side, the blood agglutinating agent 43 is present in the polymer-rich region PT and the pulp-rich region FT, and the amount of the blood agglutinating agent present in the pulp-rich region FT is greater than that of the polymer-rich region PT. The front side absorbent sheet 401a is used with the pulp-rich region FT disposed on the skin-facing surface side, but does not include the blood agglutinating agent 43. The back side absorbent sheet 401b is used with the pulp-rich region FT disposed on the non-skin-facing surface side, but does not include the blood agglutinating agent 43. According to the absorbent body 4 shown in fig. 6, in the central absorbent sheet 402 disposed inside the folded structure of 1 main absorbent sheet 401, the amount of the blood agglutinating agent 43 present is greater in the pulp-rich region FT than in the polymer-rich region PT, and therefore, even if excretion is repeated at the same absorption site, absorption inhibition due to the blood cell aggregates on the absorption surface is less likely to occur, and the effect of increasing the absorption rate is exhibited.

As shown in fig. 7, the blood agglutinating agent 43 may be disposed on the central absorbent sheet 402 having a three-layer structure including an upper absorbent sheet 402a, a middle absorbent sheet 402c, and a lower absorbent sheet 402b, and the blood agglutinating agent 43 may be disposed on the main absorbent sheet 401. In the absorbent body 4 shown in fig. 7, the front side absorbent sheet 401a formed of the main body absorbent sheet 401 is used with the pulp-rich region FT disposed on the skin-facing surface side, and the back side absorbent sheet 401b formed of the main body absorbent sheet 401 is used with the pulp-rich region FT disposed on the non-skin-facing surface side. In the front absorbent sheet 401a used with the pulp-rich region FT disposed on the skin-facing surface side, the blood agglutinating agent 43 is present in the polymer-rich region PT and the pulp-rich region FT, and the amount of the blood agglutinating agent present in the pulp-rich region FT is greater than that in the polymer-rich region PT. In the back side absorbent sheet 401b in which the pulp-rich region FT is used on the non-skin-facing surface side, in other words, the polymer-rich region PT is used on the skin-facing surface side, the blood agglutinating agent 43 is present in the polymer-rich region PT and the pulp-rich region FT, and the amount of the blood agglutinating agent present in the pulp-rich region FT is greater than that of the polymer-rich region PT. The upper absorbent sheet 402a and the intermediate absorbent sheet 402c are used with the pulp-rich region FT disposed on the skin-facing surface side, and the lower absorbent sheet 402b is used with the pulp-rich region FT disposed on the non-skin-facing surface side. In the upper absorbent sheet 402a and the intermediate absorbent sheet 402c used with the pulp-rich region FT disposed on the skin-facing surface side, the blood agglutinating agent 43 is present in the polymer-rich region PT and the pulp-rich region FT, and the amount of the blood agglutinating agent present in the pulp-rich region FT is greater than that in the polymer-rich region PT. In the lower absorbent sheet 402b in which the pulp-rich region FT is used on the non-skin-facing surface side, in other words, the polymer-rich region PT is used on the skin-facing surface side, the blood agglutinating agent 43 is present in the polymer-rich region PT and the pulp-rich region FT, and the amount of the blood agglutinating agent present in the pulp-rich region FT is greater than that of the polymer-rich region PT. According to the absorbent body 4 shown in fig. 7, since each of the absorbent sheets 401a, 401b, 402a, 402b, and 402c has the blood agglutinating agent 43, the absorption rate of blood absorption is easily increased, and the side leakage of menstrual blood can be further prevented.

As shown in fig. 4, 6, and 7, when the absorbent body 4 has a multilayer structure formed of absorbent sheets, the contained blood agglutinating agents 43 may be the same blood agglutinating agent 43 in any of the absorbent sheets 401a, 401b, 402a, 402b, and 402c, or may be different blood agglutinating agents 43.

As shown in fig. 4, 6, and 7, the absorbent sheet constituting the absorbent body 4 is formed in 2-layer regions of the polymer-rich region PT and the pulp-rich region FT, but may be formed in 3 or more layers as long as the polymer-rich region PT and the pulp-rich region FT are present.

In the sanitary napkin 1, the excretory part-facing portion B is provided with a diffusing means for diffusing menstrual blood in the longitudinal direction X, but the diffusing means may not be provided. As shown in fig. 1 to 4, the diffusing member of the sanitary napkin 1 may be a longitudinal slit 44 extending in the longitudinal direction X, or may be a diffusing member other than the longitudinal slit 44.

As shown in fig. 1 and 2, the slits 44 in the absorbent body 4 of the sanitary napkin 1 are slits extending in the longitudinal direction X, but may extend in an oblique direction having an angle with respect to both the longitudinal direction X and the transverse direction Y.

The absorbent article for menstrual blood absorption of the present invention may be a sanitary pad (pantyliner) or the like, in addition to the sanitary napkin.

The above embodiments of the present invention also disclose the following absorbent articles.

＜1＞

An absorbent article comprising an absorbent body containing a super absorbent polymer, hydrophilic fibers and a blood agglutinant, and a front sheet and a back sheet sandwiching the absorbent body,

the absorbent body has, in cross section, a polymer-rich region in which the mass ratio of the superabsorbent polymer to the total amount of the mass of the pulp and the mass of the superabsorbent polymer is relatively high, and a hydrophilic fiber-rich region in which the mass ratio is relatively low compared to the polymer-rich region,

the blood agglutinating agent is present at least in the hydrophilic fiber-rich region at a portion where the hydrophilic fiber-rich region is disposed on the skin-facing surface side for use.

＜2＞

The absorbent article according to < 1 > above, wherein the absorbent member comprises an absorbent sheet.

＜3＞

The absorbent article according to any one of the above < 1 > or < 2 >, wherein the excretion portion-facing portion of the absorbent body which is disposed so as to face the excretion portion of the wearer when worn has a diffusing means for diffusing blood in the longitudinal direction.

＜4＞

The absorbent article according to any one of the above items < 1 > to < 3 >, wherein the blood agglutinating agent is a cationic polymer.

＜5＞

The absorbent article according to < 4 > above, wherein the cationic polymer is a quaternary ammonium salt homopolymer, a quaternary ammonium salt copolymer or a quaternary ammonium salt polycondensate.

＜6＞

The absorbent article according to any one of the above items < 1 > to < 5 >, wherein the absorbent body includes an absorbent sheet, and the absorbent sheet is formed in a multilayer structure in which a plurality of the absorbent sheets are stacked in a thickness direction.

＜7＞

The absorbent article according to any one of the above < 1 > to < 6 >, wherein the absorbent body includes an absorbent sheet, and a discharge part facing portion disposed to face a discharge part of a wearer when worn has a diffusing means for diffusing blood in a longitudinal direction,

the diffusing means is a longitudinal slit extending in the longitudinal direction, and the longitudinal slit penetrates the absorbent sheet on the most skin-facing surface side containing the blood agglutinating agent.

＜8＞

The absorbent article according to any one of the above items < 1 > to < 7 >, wherein the excretion portion-facing portion of the absorbent body which is disposed so as to face the excretion portion of the wearer when worn has a diffusing means for diffusing blood in the longitudinal direction,

the diffusion unit is a longitudinal slit extending in the longitudinal direction,

the width of the longitudinal slit is 0.1mm to 1mm, preferably 0.3mm to 0.8 mm.

＜9＞

The absorbent article according to any one of the above items < 1 > to < 8 >, wherein the excretion portion-facing portion of the absorbent body which is disposed so as to face the excretion portion of the wearer when worn has a diffusing means for diffusing blood in the longitudinal direction,

the diffusion unit is a longitudinal slit extending in the longitudinal direction,

the length of the vertical slit is 10mm to 35mm, preferably 15mm to 25mm, in plan view.

＜10＞

The absorbent article according to any one of the above items < 1 > to < 9 >, wherein the excretion portion-facing portion of the absorbent body which is disposed so as to face the excretion portion of the wearer when worn has a diffusing means for diffusing blood in the longitudinal direction,

the diffusion unit is a longitudinal slit extending in the longitudinal direction,

the longitudinal slits are arranged in a plurality of rows in the transverse direction and a plurality of rows in the longitudinal direction,

the longitudinal slits in the same row are spaced from each other by 3mm to 20mm, preferably 7mm to 15 mm.

＜11＞

The absorbent article according to any one of the above items < 1 > to < 10 >, wherein the excretion portion-facing portion of the absorbent body which is disposed so as to face the excretion portion of the wearer when worn has a diffusing means for diffusing blood in the longitudinal direction,

the diffusion unit is a longitudinal slit extending in the longitudinal direction,

the longitudinal slits are arranged in a plurality of rows in the transverse direction and a plurality of rows in the longitudinal direction,

the longitudinal slits are distributed in a plurality in the same row.

＜12＞

The absorbent article according to any one of the above < 1 > to < 11 >, wherein the absorbent body includes an absorbent sheet, the absorbent sheet includes a central absorbent sheet formed at a discharge part facing portion disposed to face a discharge part of a wearer when worn, and a main absorbent sheet covering the central absorbent sheet, and a grammage of the blood coagulation agent at the discharge part facing portion is larger than a grammage of the blood coagulation agent at a peripheral portion of the discharge part facing portion.

＜13＞

The absorbent article according to < 12 > above, wherein the central absorbent sheet has a multi-layer structure in which a plurality of the absorbent sheets are stacked.

＜14＞

The absorbent article according to any one of the above items < 1 > to < 13 >, wherein the absorbent body comprises an absorbent sheet comprising a central absorbent sheet formed at a portion facing a wearer's excretory part which is disposed so as to face the wearer's excretory part when worn, and a main absorbent sheet covering the central absorbent sheet,

the central absorbent sheet comprises: the polymer-rich region and the hydrophilic fiber-rich region of the absorbent sheet are disposed at opposite positions in the thickness direction between adjacent absorbent sheets when viewed in the thickness direction.

＜15＞

The absorbent article according to any one of the above < 1 > to < 14 >, wherein the absorbent body comprises an absorbent sheet comprising a central absorbent sheet formed at a portion facing a wearer's excretory part which is disposed so as to face the wearer's excretory part when worn, and a main absorbent sheet covering the central absorbent sheet,

the central absorbent sheet has a structure in which 1 absorbent sheet is folded so as to have at least a three-layer structure, wherein the hydrophilic fiber-rich region and the polymer-rich region are arranged in the same manner in the thickness direction in an uppermost layer located on the side closest to the skin contact surface and a second layer adjacent to the uppermost layer when viewed in the thickness direction.

＜16＞

The absorbent article according to any one of the above < 1 > to < 15 >, wherein the absorbent body includes an absorbent sheet, the absorbent sheet is composed of a central absorbent sheet formed at a portion facing a wearer's excretory part which is disposed so as to face the wearer's excretory part when worn, and a main absorbent sheet covering the central absorbent sheet,

the blood agglutinant is contained only in the central absorbent sheet.

＜17＞

The absorbent article according to any one of the above < 1 > to < 15 >, wherein the absorbent body includes an absorbent sheet, the absorbent sheet is composed of a central absorbent sheet formed at a portion facing a wearer's excretory part which is disposed so as to face the wearer's excretory part when worn, and a main absorbent sheet covering the central absorbent sheet,

the blood agglutinant is contained only in the main absorbent sheet.

＜18＞

The absorbent article according to any one of the above < 1 > to < 17 >, wherein the absorbent body comprises an absorbent sheet comprising a central absorbent sheet formed at a portion facing a wearer's excretory part which is disposed so as to face the wearer's excretory part when worn, and a main absorbent sheet covering the central absorbent sheet,

the blood agglutinating agent is contained in the central absorbent sheet and the main absorbent sheet.

＜19＞

The absorbent article according to any one of < 6 > to < 18 >, wherein the absorbent body includes an absorbent sheet, and the absorbent sheet located closest to the skin contact surface side is located on the skin contact surface side when viewed in the thickness direction, and the hydrophilic fiber-rich region is located on the non-skin contact surface side.

＜20＞

The absorbent article according to any one of the above items < 1 > to < 19 >, wherein a second sheet made of a nonwoven fabric is disposed between the topsheet and the absorbent body, and the second sheet does not contain the blood agglutinating agent.

＜21＞

The absorbent article according to any one of the above items < 1 > to < 20 >, wherein the blood agglutinating agent is a cationic polymer,

the molecular weight of the cationic polymer is 2000 to 1000 ten thousand, preferably 2000 to 500 ten thousand, more preferably 2000 to 300 ten thousand, and still more preferably 1 ten to 300 ten thousand.

＜22＞

The absorbent article according to any one of the above items < 1 > to < 21 >, wherein the amount of the blood agglutinating agent is preferably 0.1g/m²Above 25g/m²Hereinafter, more preferably 0.5g/m²Above 15g/m²Hereinafter, more preferably 1.5g/m²Above 10g/m²The following.

＜23＞

An absorbent article according to any one of the above items < 1 > to < 22 > in which a water-soluble cationic polymer having a structure including a main chain and a side chain bonded to the main chain and having a molecular weight of 2000 or more is used as the blood aggregating agent, the water-soluble cationic polymer is a quaternary ammonium salt homopolymer having a repeating unit represented by the following formula 1 or a quaternary ammonium salt copolymer having a repeating unit represented by the following formula 1 and a repeating unit represented by the following formula 2, the main chain and the side chain of the water-soluble cationic polymer are bonded at 1 point, and the side chain has a quaternary ammonium moiety.

In the formula, R₁Represents H or CH₃，

n represents an integer of 1 to 10 inclusive,

represents a halide ion,

In the formula, R₃Represents H or CH₃，

m represents an integer of 1 to 10 inclusive,

to represent

＜24＞

The absorbent article according to any one of the above items < 1 > to < 23 >, wherein the blood agglutinating agent is 1g/m²Above 20g/m²The water-soluble cationic polymer of (1), which has a flow potential of 1500. mu. eq/L or more and a molecular weight of 2000 or more and comprises a quaternary ammonium salt homopolymer or a quaternary ammonium salt copolymer.

＜25＞

The absorbent article according to < 24 > above, wherein the water-soluble cationic polymer is a polymer having a structure in which the quaternary ammonium salt homopolymer or the quaternary ammonium salt copolymer has a main chain and a side chain bonded to the main chain, and the main chain and the side chain are bonded at 1 point.

＜26＞

The absorbent article according to any one of the above < 1 > to < 25 >, wherein the blood coagulant contains a water-soluble cationic polymer having a molecular weight of 2000 or more, the ratio of the inorganic value to the organic value of the water-soluble cationic polymer, i.e., the value of the inorganic value/organic value, is 0.6 or more and 4.6 or less, and the water-soluble cationic polymer is a quaternary ammonium salt homopolymer, a quaternary ammonium salt copolymer or a quaternary ammonium salt polycondensate.

＜27＞

The absorbent article according to any one of the above items < 1 > to < 26 >, wherein the absorbent article is a sanitary napkin.

Examples

Hereinafter, the absorbent article of the present invention will be described in more detail with reference to examples. However, the scope of the present invention is not limited in any way by this example.

< example 1 >

A sanitary napkin having the same basic configuration as the sanitary napkin 1 shown in fig. 1 to 3 having the absorbent body shown in fig. 4 and 5 was produced and used as a sample of example 1. As the top sheet, a sheet having a grammage of 25g/m was used²The air-through nonwoven fabric sheet of single-layer structure of (1). As the back sheet, a moisture-permeable resin film is used. As the second sheet, a sheet having a grammage of 25g/m was used²Point-bonding hot air non-woven fabric.

An absorbent sheet constituting the absorbent body was produced in accordance with example 2 of japanese patent No. 2963647. Among them, High Bulk additive hba manufactured by Weyerhauser Paper company was used as the crosslinking-treated pulp, and Aqualic CA manufactured by japan catalyst company was used as the super absorbent polymer. In the absorbent body forming step, the blood agglutinant is contained in advance in absorbent paper in which a web in which a super absorbent polymer is dispersed is superposed. Thus, the amount of the blood agglutinating agent existing in the absorbent paper as the pulp-rich region FT is larger than that of the superabsorbent polymer-dispersed web as the polymer-rich region PT. As the cationic polymer contained in the blood agglutinating agent, Merquat 106 (weight average molecular weight: 1.5 ten thousand, IOB value 2.10, streaming potential 7345. mu. eq/L) manufactured by Lubrizol Japan was used. The grammage of the cationic polymer applied to the absorbent sheet was 1.5g/m in each of the front side absorbent sheet 401a and the back side absorbent sheet 401b². As in the absorbent body shown in fig. 4, the blood agglutinating agent 43 is disposed only on the main absorbent sheet 401 having a two-layer structure including the front absorbent sheet 401a and the back absorbent sheet 401 b. That is, the blood agglutinant 43 is not disposed on the central absorbent sheet 402 forming the three-layer structure. As shown in fig. 1, a longitudinal slit is provided in the absorber.

< example 2 >

A sanitary napkin was produced in the same manner as in example 1, except that the absorbent body shown in fig. 6 was used as the absorbent body. Absorbent body as shown in fig. 6Like the absorbent body, the blood agglutinating agent 43 is disposed only on the central absorbent sheet 402 forming a three-layer structure including the upper absorbent sheet 402a, the middle absorbent sheet 402c, and the lower absorbent sheet 402 b. That is, the blood agglutinant 43 is not disposed on the main body absorbent sheet 401 having a two-layer structure including the front side absorbent sheet 401a and the back side absorbent sheet 401 b. The grammage of the cationic polymer applied to the absorbent sheet was 1.5g/m in each of the upper absorbent sheet 402a, the middle absorbent sheet 402c, and the lower absorbent sheet 402b²。

< example 3 >

A sanitary napkin was produced in the same manner as in example 1, except that the absorbent body shown in fig. 7 was used as the absorbent body. As in the absorbent body shown in fig. 7, the blood agglutinating agent 43 is disposed in the main absorbent sheet 401 having a double-layer structure including the front absorbent sheet 401a and the back absorbent sheet 401 b. Further, the blood agglutinating agent 43 is disposed on the central absorbent sheet 402 forming a three-layer structure including the upper absorbent sheet 402a, the middle absorbent sheet 402c, and the lower absorbent sheet 402 b. The gram weights of the cationic polymers applied to the absorbent sheet were 1.5g/m, respectively²。

< comparative example 1 >

The sample of comparative example 1 was produced in the same manner as in example 1, except that the absorbent body in the sample of example 1 was replaced with the absorbent body not provided with the blood agglutinating agent 43.

[ evaluation ]

The samples (sanitary napkins) of examples 1 to 3 and the sample (sanitary napkin) of comparative example 1 were evaluated for the static maximum absorption amount, the dynamic diffusion area, the static absorption time, and the static diffusion area, respectively, by the following methods. These results are shown in table 2 below.

< static maximum absorption >

Each of the samples of examples and comparative examples was developed and set on a laboratory bench, and an acrylic injection plate having an elliptic cylinder portion with a major axis of 50mm and a minor axis of 22.5mm formed integrally therewith and an acrylic injection hole with a cylinder height of 30mm formed integrally therewith was placed on the sampleThe skin-facing surface (topsheet side) of the patient was placed in a superposed manner at the center of the portion facing the excretory part, and 3g of dummy blood was injected through the inlet. After injection, the state was maintained for 3 minutes. Next, the acrylic plate with the elliptical cylinder was removed and the pressure was 50g/cm on the surface of the front sheet²The sample (2) was again placed on the acrylic plate, and after 4 minutes from the first injection, 3g of the dummy blood was additionally injected from the injection port. The injection position of the simulated blood into each sample of the examples or comparative examples was set to be the same as the position of 3g at the beginning of injection. After the second time, the same operation as in the first time was repeated, and the time when the liquid exuded from the flap portions of each of the samples of examples and comparative examples was terminated, the static maximum absorption amount was set.

As described herein, the simulated blood was obtained by preparing a ratio of blood cells and blood plasma of defibrinated horse blood (manufactured by NIPPON BIO-TEST) so that the viscosity measured with a B-type viscometer (model TVB-10M manufactured by Toyobo Co., Ltd., measurement conditions: spindle No.19, 30rpm, 25 ℃ C., 60 seconds) became 8 mPas.

< dynamic diffusion area of absorber >

Each sample of examples and comparative examples was evaluated using a movable female lumbar model described in paragraphs [0082] and [0083] of japanese patent laid-open No. 9-187476. After each sample was put on the movable female waist model and the shorts were put on, the sanitary napkin was removed from the movable female waist model and the area where the dummy blood adhered to the absorbent body was measured after injecting 2g of dummy blood to 8g at 3-minute intervals while walking at a speed of 100 steps/minute (the injection speed of the dummy blood was 15 seconds and 1 g). The measurement of the diffusion area is carried out by acquiring an image (via a CCD camera or scanner) using NEWQUBE (ver.4.20) manufactured by NEXUS as an image analyzing device.

< static absorption time >

Each of the samples of examples and comparative examples was developed and set on a laboratory bench, and on the sample, an acrylic injection plate having an acrylic injection cylinder portion of 50mm in cylinder height integrally molded with an injection hole of 1cm in diameter was positioned with the injection hole thereof on the muscle of the sampleThe center of the excretion part facing part of the skin-facing surface (front sheet side) was superposed on the skin-facing surface, and an appropriate weight plate (including the injection plate itself) was placed thereon, adjusted to a load of 0.85g/cm². The time (seconds) from the moment when the injection of the dummy blood was completed to 9g to the time when 3g of dummy blood was injected into the cylinder of the liquid injection plate at 3 minute intervals until the dummy blood in the cylinder disappeared and the front piece of the sample was exposed was measured. Each sample was measured 3 times, and the average value was taken as the static absorption time of the sample.

< static diffusion area >

The area of the dummy blood adhered to the front sheet of each sample after the measurement of the static absorption time was completed. The measurement of the diffusion area is carried out by acquiring an image (via a CCD camera or scanner) using NEWQUBE (ver.4.20) manufactured by NEXUS as an image analyzing device.

[ Table 2]

	Unit of	Example 1	Example 2	Example 3	Comparative example 1
						Maximum absorption at static state	g	15	15	18	12
Dynamic diffusion area	cm2	38	36	36	35
						Static absorption time	sec	135	130	75	155
Area of static diffusion	cm	2	7	8	8							10

From the results shown in table 2, it is understood that the sanitary napkins of examples 1 to 3 have a shorter static absorption time and a smaller static diffusion area than the sanitary napkin of comparative example 1. In addition, it is understood that the sanitary napkins of examples 1 to 3 have a larger dynamic diffusion area in the absorbent body than the sanitary napkin of comparative example 1. Therefore, the sanitary napkins of examples 1 to 3 can absorb blood more efficiently than the sanitary napkin of comparative example 1, and can prevent the side leakage of menstrual blood by increasing the absorption rate of blood.

Industrial applicability of the invention

According to the absorbent article of the present invention, blood can be efficiently absorbed into the high-absorbent polymer, the absorption rate of blood can be increased, and side leakage of menstrual blood can be prevented.

Claims (22)

1. An absorbent article characterized by:

comprises an absorbent containing a super absorbent polymer, hydrophilic fibers and a blood agglutinant, and a front sheet and a back sheet sandwiching the absorbent,

the absorbent body has, in cross section, a polymer-rich region in which the mass ratio of the super absorbent polymer to the total amount of the mass of the hydrophilic fibers and the mass of the super absorbent polymer is higher than the mass ratio of the hydrophilic fiber-rich region and a hydrophilic fiber-rich region,

the blood agglutinating agent is present at least in the hydrophilic fiber-rich region at a portion where the hydrophilic fiber-rich region is disposed on the skin-facing surface side,

the absorbent body comprises an absorbent sheet which is,

the absorbent sheet is composed of a central absorbent sheet formed at a excretory part facing part disposed to face the excretory part of the wearer when worn, and a main absorbent sheet covering the central absorbent sheet,

the central absorbent sheet has: the polymer-rich region and the hydrophilic fiber-rich region of the absorbent sheet are disposed at opposite positions in the thickness direction between adjacent absorbent sheets when viewed in the thickness direction.

2. The absorbent article of claim 1, wherein:

the absorbent body has a diffusing means for diffusing blood in the longitudinal direction at the excretion portion-facing portion.

3. The absorbent article of claim 2, wherein:

the diffusing means is a slit extending in the longitudinal direction, and the slit penetrates the absorbent sheet on the side closest to the skin-facing surface containing the blood agglutinating agent.

4. The absorbent article of claim 2 or 3, wherein:

the diffusion unit is a longitudinal slit extending in the longitudinal direction,

the width of the longitudinal slit is more than 0.1mm and less than 1 mm.

5. The absorbent article of claim 2 or 3, wherein:

the diffusion unit is a longitudinal slit extending in the longitudinal direction,

the length of the longitudinal slit is 10mm to 35mm in plan view.

6. The absorbent article of claim 2 or 3, wherein:

the diffusion unit is a longitudinal slit extending in the longitudinal direction,

the longitudinal slits are arranged in a plurality of rows in the transverse direction and a plurality of rows in the longitudinal direction,

the longitudinal slits in the same row are spaced from each other by 3mm to 20 mm.

7. The absorbent article of claim 2 or 3, wherein:

the diffusion unit is a longitudinal slit extending in the longitudinal direction,

the longitudinal slits are arranged in a plurality of rows in the transverse direction and a plurality of rows in the longitudinal direction,

the longitudinal slits are distributed in a plurality in the same row.

8. The absorbent article according to any one of claims 1 to 3, wherein:

the blood agglutinating agent is a cationic polymer.

9. The absorbent article of claim 8, wherein:

the cationic polymer is a quaternary ammonium salt homopolymer, a quaternary ammonium salt copolymer or a quaternary ammonium salt polycondensate.

10. The absorbent article of claim 8, wherein:

the molecular weight of the cationic polymer is 2000-1000 ten thousand.

11. The absorbent article according to any one of claims 1 to 3, wherein:

the grammage of the blood agglutinating agent at the excretion portion-facing portion is greater than the grammage of the blood agglutinating agent at the peripheral portion of the excretion portion-facing portion.

12. The absorbent article according to any one of claims 1 to 3, wherein:

the central absorbent sheet has a structure in which 1 absorbent sheet is folded so as to have a three-layer structure, wherein the hydrophilic fiber-rich region and the polymer-rich region are arranged in the same manner in the thickness direction in an uppermost layer located on the side closest to the skin contact surface and a second layer adjacent to the uppermost layer when viewed in the thickness direction.

13. The absorbent article according to any one of claims 1 to 3, wherein:

the blood agglutinating agent is contained only in the central absorbent sheet.

14. The absorbent article according to any one of claims 1 to 3, wherein:

the blood agglutinating agent is contained only in the main absorbent sheet.

15. The absorbent article according to any one of claims 1 to 3, wherein:

the blood agglutinating agent is contained in the central absorbent sheet and the main absorbent sheet.

16. The absorbent article according to any one of claims 1 to 3, wherein:

a second sheet made of a nonwoven fabric is disposed between the top sheet and the absorbent body, and the second sheet does not contain the blood agglutinating agent.

17. The absorbent article according to any one of claims 1 to 3, wherein:

the amount of the blood agglutinant is 0.1g/m²Above 25g/m²The following.

18. The absorbent article according to any one of claims 1 to 3, wherein:

an absorbent article using, as the blood aggregating agent, a water-soluble cationic polymer having a structure comprising a main chain and a side chain bonded to the main chain and having a molecular weight of 2000 or more, wherein the water-soluble cationic polymer is a quaternary ammonium salt homopolymer having a repeating unit represented by the following formula 1 or a quaternary ammonium salt copolymer having a repeating unit represented by the following formula 1 and a repeating unit represented by the following formula 2, the main chain and the side chain of the water-soluble cationic polymer are bonded at 1 point, and the side chain has a quaternary ammonium moiety,

in the formula, R₁Represents H or CH3, and is represented by,

R₂to represent

n represents an integer of 1 to 10 inclusive,

represents a halide ion,

In the formula, R₃Represents H or CH₃，

R₄To represent

m represents an integer of 1 to 10 inclusive,

to represent

Or

19. The absorbent article according to any one of claims 1 to 3, wherein: as the blood agglutinant, 1g/m²Above 20g/m²The water-soluble cationic polymer has a flow potential of 1500 [ mu ] eq/L or more and a molecular weight of 2000 or more, and contains a quaternary ammonium salt homopolymer or a quaternary ammonium salt copolymer.

20. The absorbent article of claim 19, wherein:

the water-soluble cationic polymer is a polymer of which the quaternary ammonium salt homopolymer or the quaternary ammonium salt copolymer has a structure of a main chain and a side chain bonded with the main chain, and the main chain is bonded with the side chain at 1 point.

21. The absorbent article according to any one of claims 1 to 3, wherein:

the blood coagulant contains a water-soluble cationic polymer having a molecular weight of 2000 or more, wherein the ratio of the inorganic value to the organic value of the water-soluble cationic polymer, i.e., the ratio of the inorganic value to the organic value, i.e., the value of the inorganic value/organic value, is 0.6 or more and 4.6 or less, and the water-soluble cationic polymer is a quaternary ammonium salt homopolymer, a quaternary ammonium salt copolymer or a quaternary ammonium salt polycondensate.

22. The absorbent article according to any one of claims 1 to 3, wherein:

the absorbent article is a sanitary napkin.

Images